Sucampo Pharmaceuticals 10-K 9 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 02, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		44,900,719
Entity Public Float			$99,600,000
Amendment Flag	FALSE
Entity Central Index Key	1365216
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$71,622	$44,102
Investments, current	22,393	16,003
Product royalties receivable	18,576	14,829
Accounts receivable, net	5,338	5,407
Deferred tax assets, current	476	2,028
Deferred charge, current	295	673
Restricted cash, current	213	26,115
Inventory		209
Prepaid expenses and other current assets	3,411	3,987
Total current assets	122,324	113,353
Investments, non-current	13,540	7,219
Property and equipment, net	763	1,156
Intangible assets, net	151	6,438
Deferred tax assets, non-current	571	1,212
Deferred charge, non-current	1,695	4,540
Restricted cash, non-current	2,224	2,471
Other assets	306	488
Total assets	141,574	136,877
Current liabilities:
Accounts payable	4,143	7,614
Accrued expenses	8,467	5,682
Deferred revenue, current	2,051	1,365
Collaboration obligation	6,000
Income tax payable	1,291	701
Notes payable, current	8,240	26,892
Other current liabilities	3,618	358
Total current liabilities	33,810	42,612
Notes payable, non-current	17,578	25,828
Deferred revenue, non-current	5,118	6,169
Deferred tax liability, non-current	820	2,066
Other liabilities	1,936	1,233
Total liabilities	59,262	77,908
Commitments and contingencies (Notes 8 and 11)
Stockholders' equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized at December 31, 2014 and 2013; no shares issued and outstanding at December 31, 2014 and 2013	0	0
Additional paid-in capital	83,646	72,109
Accumulated other comprehensive income	14,265	15,601
Treasury stock, at cost; 524,792 shares at December 31, 2014 and 2013	-2,313	-2,313
Accumulated deficit	-13,732	-26,860
Total stockholders' equity	82,312	58,969
Total liabilities and stockholders' equity	141,574	136,877
Common Class A [Member]
Stockholders' equity:
Common stock value	446	432
Common Class B [Member]
Stockholders' equity:
Common stock value	$0	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792
Common Class A [Member]
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	44,602,988	43,315,749
Common stock, shares outstanding	44,602,988	43,315,749
Common Class B [Member]
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Research and development revenue	$7,246	$20,354	$21,545
Product royalty revenue	62,775	52,100	50,696
Product sales revenue	33,252	16,425	5,037
Co-promotion revenue	3,360	61	3,576
Contract and collaboration revenue	8,817	654	633
Total revenues	115,450	89,594	81,487
Costs and expenses:
Costs of goods sold	16,269	12,402	3,030
Intangible assets impairment	5,631
Research and development	20,566	21,524	21,292
General and administrative	31,230	25,413	30,157
Selling and marketing	14,523	21,059	18,691
Total costs and expenses	88,219	80,398	73,170
Income from operations	27,231	9,196	8,317
Non-operating income (expense):
Interest income	172	124	179
Interest expense	-1,520	-1,894	-2,346
Other income, net	1,250	3,517	1,827
Total non-operating income (expense), net	-98	1,747	-340
Income before income taxes	27,133	10,943	7,977
Income tax provision	-14,005	-3,928	-2,916
Net income	13,128	7,015	5,061
Net income per share:
Basic (in Dollars per share)	$0.30	$0.17	$0.12
Diluted (in Dollars per share)	$0.29	$0.16	$0.12
Weighted average common shares outstanding:
Basic (in Shares)	43,691	41,716	41,660
Diluted (in Shares)	44,506	42,544	41,785
Net income	13,128	7,015	5,061
Other comprehensive income (loss):
Unrealized loss on pension benefit obligation	-978
Unrealized gain (loss) on investments, net of tax effect	-7	2	36
Foreign currency translation	-351	-567	-1,724
Total comprehensive income	$11,792	$6,450	$3,373

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Changes in Stockholdersb Equity (Deficit) (USD $)	Common Class A [Member]	Common Class B [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
	Common Stock [Member]	Common Stock [Member]
Balance at Dec. 31, 2011	$157,000	$262,000	$59,957,000	$17,854,000	($700,000)	($38,936,000)	$38,594,000
Balance (in Shares) at Dec. 31, 2011	15,690,780	26,191,050			186,987
Conversion of shares	262,000	-262,000
Conversion of shares (in Shares)	26,191,050	-26,191,050
Employee stock option expense			2,233,000				2,233,000
Stock issued upon exercise of stock options	1,000		311,000				312,000
Stock issued upon exercise of stock options (in Shares)	79,525
Stock issued under employee stock purchase plan			20,000				20,000
Stock issued under employee stock purchase plan (in Shares)	3,550
Foreign currency translation				-1,724,000			-1,724,000
Unrealized loss on investments, net of tax effect				36,000			36,000
Treasury stock, at cost					-1,277,000		-1,277,000
Treasury stock, at cost (in Shares)					270,043
Net income						5,061,000	5,061,000
Balance at Dec. 31, 2012	420,000		62,521,000	16,166,000	-1,977,000	-33,875,000	43,255,000
Balance (in Shares) at Dec. 31, 2012	41,964,905				457,030
Employee stock option expense			1,744,000				1,744,000
Stock issued upon exercise of stock options	5,000		2,332,000				2,337,000
Stock issued upon exercise of stock options (in Shares)	597,836
Stock issued under employee stock purchase plan			25,000				25,000
Stock issued under employee stock purchase plan (in Shares)	3,625
Stock issued under "at-the-market" offering	7,000		5,274,000				5,281,000
Stock issued under "at-the-market" offering (in Shares)	749,383
Foreign currency translation				-567,000			-567,000
Unrealized loss on investments, net of tax effect				2,000			2,000
Windfall tax benefit from stock-based compensation			213,000				213,000
Treasury stock, at cost					-336,000		-336,000
Treasury stock, at cost (in Shares)					67,762
Net income						7,015,000	7,015,000
Balance at Dec. 31, 2013	432,000		72,109,000	15,601,000	-2,313,000	-26,860,000	58,969,000
Balance (in Shares) at Dec. 31, 2013	43,315,749				524,792
Employee stock option expense			2,287,000				2,287,000
Stock issued upon exercise of stock options	9,000		3,780,000				3,789,000
Stock issued upon exercise of stock options (in Shares)	742,865
Stock issued under employee stock purchase plan			36,000				36,000
Stock issued under employee stock purchase plan (in Shares)	5,853
Stock issued under "at-the-market" offering	5,000		5,321,000				5,326,000
Stock issued under "at-the-market" offering (in Shares)	538,521
Foreign currency translation				-351,000			-351,000
Unrealized loss on investments, net of tax effect				-7,000			-7,000
Windfall tax benefit from stock-based compensation			113,000				113,000
Unrealized loss on pension benefit obligation				-978,000			-978,000
Net income						13,128,000	13,128,000
Balance at Dec. 31, 2014	$446,000		$83,646,000	$14,265,000	($2,313,000)	($13,732,000)	$82,312,000
Balance (in Shares) at Dec. 31, 2014	44,602,988				524,792

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	$13,128	$7,015	$5,061
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,090	1,488	1,488
Intangible assets impairment	5,631
Deferred tax provision (benefit)	770	-1,678	-23,026
Deferred charge	3,223	673	23,922
Stock-based compensation	2,287	1,744	2,233
Amortization of premiums on investments	82	110	67
Notes payable paid-in-kind interest			2,024
Unrealized currency translation gains	-1,146	-2,023	-1,300
Shortfall from stock-based compensation	-227
Changes in operating assets and liabilities:
Accounts receivable	67	-4,047	3,256
Unbilled accounts receivable		732	1,303
Product royalties receivable	-3,747	-654	-3,380
Inventory	206	-163	87
Prepaid and income taxes receivable and payable, net	592	560	2,998
Accounts payable	-3,437	2,242	-1,453
Accrued expenses	2,868	-4,685	15
Deferred revenue	-191	-3,126	-95
Collaboration obligation	6,000
Accrued interest payable	-32	-32
Other assets and liabilities, net	3,714	-2,365	-1,200
Net cash provided by (used in) operating activities	30,878	-4,209	12,000
Cash flows from investing activities:
Purchases of investments	-29,153	-10,127	-23,609
Proceeds from the sales of investments	1,700	755	750
Maturities of investments	14,650	6,485	27,790
Purchases of property and equipment	-66	-168	-439
Purchases of intangible assets			-3,000
Purchase of other investing activities			-432
Changes in restricted cash	25,828	-9,561	-1,649
Net cash provided by (used in) investing activities	12,959	-12,616	-589
Cash flows from financing activities:
Proceeds from notes payable		10,600
Repayment of notes payable	-24,904	-7,539	-7,500
Proceeds from exercise of stock options	3,789	2,337	311
Proceeds from employee stock purchase plan	36	25	20
Proceeds from "at-the market" stock issuance	5,326	5,281
Purchase of treasury stock		-336	-1,277
Windfall benefit from stock-based compensation	340	213
Net cash provided by (used in) financing activities	-15,413	10,581	-8,446
Effect of exchange rates on cash and cash equivalents	-904	-1,676	-1,605
Net increase (decrease) in cash and cash equivalents	27,520	-7,920	1,360
Cash and cash equivalents at beginning of period	44,102	52,022	50,662
Cash and cash equivalents at end of period	71,622	44,102	52,022
Supplemental cash flow disclosures:
Cash paid for interest	129	156	157
Tax refunds received	76	103	3,658
Tax payments made	$9,166	$4,939	$3,665

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Organization and Basis of Presentation
	Description of the Business
	Sucampo Pharmaceuticals, Inc., (Company) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to meet major unmet medical needs.
	The Company is currently focused on developing compounds known as prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of the Company’s drug technologies.
	The Company currently generates revenue mainly from product royalties, development milestone payments, product sales and clinical development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for approved products and other compounds, seeks global partnering opportunities for its approved products and compounds, and seeks strategic opportunities for in-licensing non-prostone clinical candidates.
	AMITIZA is being marketed in the U.S. for three gastrointestinal indications under the October 2014 collaboration and license agreement (North America Takeda Agreement) with Takeda Pharmaceutical Company Limited (Takeda). These indications are chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults. Takeda also holds marketing rights to AMITIZA in Canada, but has not yet commercialized it there. The Company is primarily responsible for clinical development activities under the North America Takeda Agreement while Takeda is primarily responsible for commercialization of AMITIZA in the U.S. and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the U.S. for the treatment of CIC in April 2006, for the treatment of IBS-C in May 2008 and for the treat of OIC in May 2013. In October 2014, the Company and Takeda executed amendments to the North America Takeda Agreement as well as to the ancillary agreements which, among other things, extended the term of the North America Takeda Agreement beyond December 2020. During the extended term, the Company will split the annual net sales revenue of the branded AMITIZA products. In addition, beginning in April 2015, Takeda will no longer reimburse the Company for the product details performed by the Company’s sales force or for promotional materials used by the sales force. As a result, the Company will not use a sales force to promote AMITIZA after the end of 2014.
	In October 2014, the Company and its affiliate, Sucampo AG, (SAG) (the Company and SAG together, Company Entities), along with R-Tech Ueno, Ltd. (R-Tech), Takeda and certain affiliates of Takeda (collectively, Takeda Pharmaceutical) executed a settlement and license agreement (Settlement and License Agreement) with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (the foregoing three entities collectively, Par) that resolves the patent litigation in the U.S. related to the Company’s AMITIZA (lubiprostone) 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule product. Under the terms of the Settlement and License Agreement, the Company Entities and R-Tech will grant Par a non-exclusive license to market Par’s generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule (collectively, Licensed Products) in the U.S. for the indications approved for AMITZA beginning on January 1, 2021, or earlier under certain circumstances. Also beginning on January 1, 2021, the Company Entities will split the gross profits of the Licensed Products sold during the term of the Settlement and License Agreement, which continues until each of the Company’s patents has expired. In the event Par elects to launch an authorized generic product, the Company will supply Par with the product under the terms of a manufacturing and supply agreement at a negotiated price. Additionally, the Company Entities, R-Tech, Takeda Pharmaceutical, and Par have agreed to dismiss with prejudice the patent litigation filed against Par in the U.S. District Court for the District of Delaware.
	In Japan, lubiprostone is being developed and marketed under a license, commercialization and supply agreement (Japan Abbott Agreement) with Abbott Japan Co. Ltd., (Abbott) for the treatment of CIC in Japan. The Company received approval of its new drug application, (NDA) for AMITIZA for the treatment of chronic constipation, (CC) excluding constipation caused by organic diseases, from the Ministry of Health, Labour and Welfare in June 2012 and pricing approval in November 2012. In early December 2013, the two-week limitation on prescriptions, generally applied to all new approvals of products for the first year after reimbursement price approval, was removed. AMITIZA is Japan’s only prescription medicine for CC. On February 27, 2015, Abbott Laboratories, Inc. and Mylan, Inc. (Mylan) closed Mylan’s purchase of Abbott’s non-U.S. developed markets specialty and branded generics business. The Company does not expect any significant changes in the commercialization of AMITIZA in Japan as a result of such transfer. Under the terms of the Japan Abbott Agreement, the Company received a commercial milestone payment of $2.5 million during the third quarter of 2014 for the first occurrence of annual net sales of lubiprostone in Japan exceeded ¥5.0 billion.
	In the U.K., the Company received approval in September 2012 from the Medicines and Healthcare Products Regulatory Agency (MHRA) for the use of AMITIZA to treat CIC. The Company filed for the OIC indication, but in March 2014 the Company received notification from MHRA that the application for the OIC indication was not approved and we have since resubmitted the application for OIC for re-review to MHRA. The Company currently awaits MHRA’s decision on the OIC indication. The Company made AMITIZA available in the U.K. in the fourth quarter of 2013. In July 2014, National Institute of Health and Care Excellence (NICE) published the technology appraisal guidance recommending the use of AMITIZA in the treatment of CIC and associated symptoms in adults who have failed laxatives. In January 2015, the Company successfully completed the European mutual recognition procedure (MRP) for AMITIZA for the treatment of CIC in select European countries, resulting in a recommendation for marketing authorization.
	In Switzerland, AMITIZA was approved to treat CIC in 2009. In 2012, the Company reached an agreement with the Bundesamt fur Gesundheit, (BAG), the Federal Office of Public Health in Switzerland, on a reimbursement price for AMITIZA in Switzerland, and began active marketing in the first quarter of 2013. Since February 2012, AMITIZA has also been available through a Named Patient Program throughout the European Union, Iceland and Norway. In February 2014, the Company announced that the BAG revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Spezialitätenliste to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine month period. In July 2014, AMITIZA was approved for the treatment of OIC in chronic, non-cancer adult patients by the Swissmedic, the Swiss Agency for Therapeutic Products.
	In October 2014, SAG and Takeda’s affiliate, Takeda Pharmaceuticals International GmbH Limited, entered into an exclusive global license agreement (Global License Agreement) to develop and commercialize AMITIZA. The territories excluded from the Global License Agreement are Canada, the U.S., Japan and the People’s Republic of China. Canada and the U.S. are covered by the North America Takeda Agreement, and Japan is covered by the Japan Abbott Agreement. The Global License Agreement is effective until it expires on a country-by-country basis on the fourteenth (14th) anniversary of the date of first commercial sale in that country. Under the terms of the Global License Agreement, SAG will receive a nonrefundable upfront payment of $14 million from Takeda for exclusive rights to develop and commercialize AMITIZA in the global markets covered by the Global License Agreement. In addition, SAG will also be eligible for up to $35 million in additional commercial milestone payments contingent on the achievement of certain net sales revenue targets. Takeda will be responsible for all development activities and costs, except that SAG will assume responsibility for the first $6 million in development expenses incurred by Takeda. SAG will supply Takeda with AMITIZA at a negotiated supply price. In addition, Takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities for AMITIZA in the territories covered by the Global License Agreement.
	The Company holds license agreements for RESCULA in the U.S. and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China (R-Tech Territory). A supplemental new drug application (sNDA) for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension was approved by the U.S. Food and Drug Administration (FDA) in December 2012, and the Company began commercializing the product in February 2013. According to the approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a big potassium channel activator, which is different from other IOP lowering agents. The Company has ceased marketing RESCULA in the fourth quarter of 2014, and in the third quarter of 2014 the Company incurred a $5.6 million intangible assets impairment related to RESCULA. In February 2015, the Company alerted physicians that it has ceased to manufacture the product.
	The Company’s other clinical development programs include the following:
	New Formulation of Lubiprostone
	The Company has been developing a new formulation of lubiprostone, both for adult and pediatric patients who are unable to take capsules and for naso-gastric tube fed patients. Takeda is funding 100% of the costs of this new formulation work and the Company expects to initiate a phase 3 trial in the second half of 2015.
	Pediatric Functional Constipation
	Two of the four planned phase 3 studies for the Company’s pediatric functional constipation development program are ongoing, both of which are testing the soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age. The third planned phase 3 study, a 12-week, randomized, placebo-controlled trial was initiated in December 2013. The remaining planned phase 3 study, a follow-on, long-term safety extension study, was initiated in March 2014. The Company is also evaluating the timing of the initiation of the second pivotal trial in our phase 3 program for pediatric functional constipation in children aged 6 months to less than 6 years, which will require the new formulation.
	Cobiprostone for Oral Mucositis
	In the first quarter of 2014, the Company completed its phase 1b trial that evaluated the safety and pharmacokinetics of an oral spray formulation of cobiprostone. The results of this phase 1b trial showed that cobiprostone was well-tolerated overall and revealed low systematic exposure. The next phase of clinical development, a phase 2a trial, is expected to begin at the end of the first half of 2015.
	Cobiprostone for Non-Erosive Reflux Disease (NERD)
	The Company announced it will begin a development program for cobiprostone to treat NERD for patients who have a non-satisfactory response to proton pump inhibitors. The Company initiated a phase 2 program in NERD at the end of 2014.
	Unoprostone Isopropyl for Retinitis Pigmentosa (RP)
	In the first half of 2015, the Company will obtain interim, one-year data from the two-year phase 3 study for RP in Japan, which is being funded by R-Tech. The Company continues to work with clinical experts and regulators in the U.S. and Europe to determine a go-forward plan for development of RP in these markets should results from the Japanese study prove supportive. Taken together, these efforts will provide the Company with the information needed to decide on the next steps in RP by mid-2015.
	Unoprostone Isopropyl Geographic Atrophy (GA)
	A small trial to establish proof of activity has been carried out by a clinical investigator in Japan, who showed that treatment with unoprostone for over one year delayed the loss of functional retinal area in patients with GA in comparison with the placebo control.
	Basis of Presentation
	The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. of America, (GAAP) and the rules and regulations of the Securities and Exchange Commission, (SEC). The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: SAG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts operations in North and South America and Sucampo Pharma Europe, Ltd., based in Oxford, U.K. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Revisions to Previously Issued Financial Statements
	While preparing historical financial statements for the year ended December 31, 2013 and quarters ended March 31, 2014 and June 30, 2014, the Company identified certain immaterial errors in the presentation of certain line items in the previously reported financial statements. In accordance with ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated these errors and, based on an analysis of quantitative and qualitative factors, determined that they were not material, individually or in aggregate, to any previously issued financial statements and, therefore, amendment of previously filed reports with the SEC was not required. The Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings.
	The Company has revised the Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2013 and 2012, the three months March 31, 2014, and the Consolidated Balance Sheets as of December 31, 2013 and 2012 to correct errors in the recognition of indirect taxes at its Swiss subsidiary. The errors affect the years ended December 31, 2012 and 2013 and the periods ended March 31, 2013, June 30, 2013, September 30, 2013 and March 31, 2014. During those periods, the Company overstated its indirect tax liability and understated net income.
	The Company has also revised the Consolidated Statements of Cash Flows for the year ended December 31, 2013 to correct errors in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents and the change in net income. The errors in classification affect the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013. These errors have no effect on the balances of cash and cash equivalents.
	Selected Items - Annual	As			Revision			As
		Previously			Adjustment			Revised
		Reported
	Consolidated Balance Sheet
	(In thousands)	Presentation as of December 31, 2013
	Other assets	$	584		$	(96	)	$	488
	Total assets		136,973			(96	)		136,877
	Other liabilities		2,150			(917	)		1,233
	Total liabilities		78,825			(917	)		77,908
	Accumulated deficit		(27,681	)		821			(26,860	)
	Total stockholders' equity		58,148			821			58,969
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands)	Presentation as of the year ended December 31, 2012
	Other income (expense), net	$	1,602		$	225		$	1,827
	Total non-operating income (expense), net		(565	)		225			(340	)
	Income (loss) before income taxes		7,752			225			7,977
	Net income		4,836			225			5,061
	Comprehensive income		3,148			225			3,373
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands, except per share data)	Presentation as of the year ended December 31, 2013
	Other income (expense), net	$	2,921		$	596		$	3,517
	Total non-operating income (expense), net		1,151			596			1,747
	Income (loss) before income taxes		10,347			596			10,943
	Net income		6,419			596			7,015
	Net income per share: Basic		0.15			0.02			0.17
	Net income per share: Diluted		0.15			0.01			0.16
	Comprehensive income		5,854			596			6,450
	Consolidated Statements of Cash Flows
	(In thousands)	Presentation as of the year ended December 31, 2013
	Net cash provided by (used in) operating activities	$	(5,418	)	$	1,209		$	(4,209	)
	Net cash provided by (used in) investing activities		(13,881	)		1,265			(12,616	)
	Effect of exchange rates on cash and cash equivalents		798			(2,474	)		(1,676	)
Selected Items - Quarterly	As			Revision			As
	Previously			Adjustment			Revised
	Reported
Consolidated Balance Sheet
(In thousands)	Presentation as of March 31, 2014
Other Assets	$	455		$	28		$	483
Other liabilities		1,596			(917	)		679
Total liabilities		78,839			(917	)		77,922
Accumulated deficit		(27,006	)		945			(26,061	)
Total stockholders' equity		65,406			945			66,351
Consolidated Statements of Operations and Comprehensive Income
(In thousands)	Presentation as of the three months ended March 31, 2014
Other income (expense), net	$	(323	)	$	124		$	(199	)
Total non-operating income (expense), net		(666	)		124			(542	)
Income (loss) before income taxes		1,939			124			2,063
Income tax benefit (provision)		(1,264	)		(44	)		(1,308	)
Net income		675			80			755
Comprehensive income		564			80			644

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	Cash and Cash Equivalents
	For the purpose of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase.
	Restricted Cash
	Restricted cash at December 31, 2014 primarily represented collateral pledged to support a loan guarantee and development agreement (Numab Agreement) between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $2.4 million at December 31, 2014.
	Restricted cash at December 31, 2013 primarily represented collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd. (Tokyo-Mitsubishi Bank); a loan agreement with The Mizuho Bank, Ltd. (Mizuho Bank); the Numab Agreement, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at December 31, 2013.
	Current and Non-Current Investments
	Current and non-current investments consist primarily of U.S. government agency securities, certificates of deposit, corporate bonds, municipal securities and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available-for-sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of December 31, 2014 and 2013, approximately $37.0 million, or 33.6%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or U.S. government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 71.3%, 81.3% and 74.4% of the Company’s total revenues for the years ended December 31, 2014, 2013 and 2012, respectively. Accounts receivable and product royalties receivable from Takeda accounted for 88.5% and 88.2% of the Company’s total accounts receivable and product royalties receivable at December 31, 2014 and 2013. Revenues from another unrelated party, Abbott, accounted for 27.8%, 17.6% and 19.3% of the Company’s total revenues for the years ended December 31, 2014, 2013 and 2012. The Company depends significantly upon collaborations with Takeda and Abbott, and its activities may be impacted if these relationships are disrupted (see Note 14).
	The Company has an exclusive supply arrangement with R-Tech to provide the Company with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations (see Note 12).
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the Notes (as defined below) payable at December 31, 2014 and 2013 were less than the estimated fair values (see Note 13.) The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
	Accounts Receivable
	Accounts receivable primarily represents amounts due under the North America Takeda Agreement and Japan Abbott Agreement. The Company recorded an allowance for doubtful accounts of approximately $25,000 and $440,000 at December 31, 2014 and 2013, respectively, related to certain disputed Takeda invoices. Accounts receivable of approximately $779,000 was charged off against the allowance for doubtful accounts during the year ended December 31, 2014.
	Property and Equipment
	Property and equipment are recorded at cost and consist of computer and office machines, furniture and fixtures, and leasehold improvements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer and office machines are depreciated over four years and furniture and fixtures are depreciated over seven years. Leasehold improvements are amortized over the shorter of ten years or the life of the lease. Significant additions and improvements are capitalized. Expenditures for maintenance and repairs are charged to earnings as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in earnings.
	Impairment Evaluation for Long-lived Assets
	The Company reviews definite lived intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. The carrying value of an intangible asset is assessed for impairment whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. The amount of impairment loss recognized is the amount the carrying value exceeds its fair value (see Note 6).
	Revenue Recognition
	The Company’s revenues are derived primarily from product royalties, product sales, development milestone payments, clinical development activities, contract and collaboration activities,].
	Multiple-Element Arrangements
	The Company evaluated the multiple deliverables within the AMITIZA agreements in accordance with the guidance of multiple deliverables under ASC 605-25 to determine whether the deliverables can be separated for revenue recognition purposes. The separation criteria include whether the deliverables have standalone value and whether objective reliable evidence of fair value exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. The Company’s deliverables under AMITIZA agreements are more fully described in Note 14 below.
	Where agreements include contingent milestones the Company evaluates whether each milestone is substantive. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Where milestones are not considered substantive their treatment is based on either a time-based or proportional performance model.
	Research and Development Revenue
	The Company applied a time-based model of revenue recognition for cash flows associated with research and development deliverables agreed upon prior to January 1, 2011 under the North America Takeda Agreement. Under this model, cash flow streams related to each unit of accounting are recognized as revenue over the estimated performance period. Upon receipt of cash payments, such as development milestones, revenue is recognized to the extent the accumulated service time has occurred. The remainder is deferred and recognized as revenue ratably over the remaining estimated performance period.
	For research and development deliverables agreed upon subsequent to January 1, 2011 which are reimbursable by Takeda at contractually predetermined percentages, the Company recognizes revenue when the underlying research and development expenses are incurred, assuming all other revenue recognition criteria are met.
	Product Royalty Revenue
	Product royalty revenue represents royalty revenue earned on net sales of AMITIZA under the North America Takeda Agreement, and is recorded on an accrual basis when earned in accordance with contractual terms, collectability is reasonably assured and all other revenue recognition criteria are met.
	Product Sales Revenue
	Product sales revenue consists of AMITIZA sales under the Japan Abbott Agreement, the Global License Agreement, and prior to the Global License Agreement, by the Company in Europe, and RESCULA sales by the Company in the U.S. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return. There have been no product sales as of December 31, 2014 under the Global License Agreement.
	RESCULA product sales consist of RESCULA sales in the U.S. The Company recognizes revenue from RESCULA product sales less deductions for estimated sales discounts and sales returns. Revenue from product sales of RESCULA is recognized when persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and collectability is reasonably assured. The Company accounts for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product prior to and up to 12 months subsequent to the product’s labeled expiration date. As a result, the Company estimates an accrual for product returns, which is recorded as a reduction of product sales. Given the Company’s limited history of selling RESCULA and the return period, the Company cannot reasonably estimate product returns from the wholesale distribution channel. Therefore, the Company is deferring the recognition of revenue until there is confirmation of pull-through sales to end-user customers. The Company has ceased marketing RESCULA during the third quarter of 2014 and all remaining inventory is set to expire during March 2015.
	The Company’s three largest wholesale customers accounted for 89.0% and 96.2% of its RESCULA product sales for the years ended December 31, 2014 and 2013, respectively.
	Co-promotion Revenue
	Takeda reimbursements of co-promotion costs under the North America Takeda Agreement, including costs associated with the Company’s specialty sales force and miscellaneous marketing activities, are recognized as co-promotion revenue as the related costs are incurred and Takeda becomes contractually obligated to pay the amounts. We have determined that we are acting as a principal under this agreement, and as such, we record reimbursements of these amounts on a gross basis as co-promotion revenue. In December 2014, as a result of the amendment to the North America Takeda Agreement, we ceased co-promoting AMITIZA.
	Contract and Collaboration Revenue
	Contract and Collaboration revenue relates to development and consulting activities and includes $8.0 million of the upfront payment received from Takeda in 2014 under the Global License Agreement.
	The Company considers its participation in joint committees under the Japan Abbott Agreement and North America Takeda Agreement as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts.
	Deferred Revenue
	Deferred revenue represents payments received for licensing fees, option fees, consulting, research and development contracts and related cost sharing and supply agreements, mainly with Takeda, Abbott and R-Tech, which are deferred until revenue can be recognized under the Company’s revenue recognition policy. Deferred revenue also includes product sales of RESCULA that are deferred until the product is sold to end-user customers or until wholesale customers return the product to the Company. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within 12 months of the balance sheet date. At December 31, 2014 and 2013, total deferred revenue was approximately $7.2 million and $7.5 million, respectively.
	Total deferred revenue consists of the following as of:
			December 31,
	(In thousands)		2014			2013
	Deferred revenue, current		$	2,051		$	1,365
	Deferred revenue, non-current			5,118			6,169
			$	7,169		$	7,534
	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current		$	453		$	477
	Deferred revenue to related parties, non-current			4,141			4,925
	Total		$	4,594		$	5,402
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses from third parties who conduct research and development activities pursuant to development and consulting agreements on behalf of the Company. Costs related to the acquisition of intellectual property are expensed as incurred in research and development expenses since the underlying technology associated with such acquisitions is unproven, has not received regulatory approval at its early stage of development and does not have alternative future uses. Milestone payments due under agreements with third party contract research organizations (CROs) are accrued when it is considered probable that the milestone event will be achieved.
	Accrued Research and Development Expenses
	As part of the process of preparing Consolidated Financial Statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company’s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external CROs and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment; invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes significant judgments and estimates in determining the accrued balance in any accounting period. No material adjustments have been required for this accrual during the years ended December 31, 2014 and 2013.
	Employee Stock-Based Compensation
	The Company’s determination of fair value of share-based awards on the date of grant using an option-pricing model is affected by the Company’s stock price and assumptions regarding several subjective variables. The assumptions used to estimate the fair value of stock options granted for the years ended December 31, 2014, 2013 and 2012 were as follows:
		Year Ended December 31,
		2014			2013			2012
	Expected volatility	70%	-	72%	65%	-	75%	62%	-	64%
	Risk-free interest rate	1.63%	-	2.01%	1.23%	-	1.40%	0.76%	-	1.60%
	Expected term (in years)	5.28	-	6.25	5.5	-	6.25	5.5	-	6.25
	Expected dividend yield		0%			0%			0%
	Expected Volatility: expected volatility is calculated using the Company’s historical stock prices.
Risk-Free Interest Rate: the risk-free interest rate is based on the market yield currently available on U.S. Treasury securities with a maturity that approximates the expected term of the share-based awards.
Expected Term: the Company elected to use the “simplified” method to calculate the expected term of share-based awards. The Company has used a lattice based model to determine the expected term for market condition share-based awards.
Expected Dividend Yield: the Company has not paid, and does not anticipate paying, any dividends in the foreseeable future.
Employee stock-based compensation expense for the years ended December 31, 2014, 2013 and 2012 has been reduced for estimated forfeitures as such expense is based upon awards expected to ultimately vest. Accounting guidance on share-based payments requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the years ended December 31, 2014, 2013 and 2012, the estimated forfeiture rate ranged from 10.0% to 30.94%.
Employee stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2014, 2013 and 2012 was as follows:
		Year Ended December 31,
(In thousands)		2014			2013			2012
Research and development expense		$	349		$	293		$	535
General and administrative expense			1,816			1,260			1,349
Selling and marketing expense			122			191			349
Total			2,287			1,744			2,233
Employee stock-based compensation expense per basic and diluted share of common stock		$	0.05		$	0.04		$	0.05
Income Taxes
The Company accounts for income taxes under the asset and liability method in accordance with the relevant accounting guidance for income taxes. Under the asset and liability method, the current income tax provision or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in the income tax provision during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carry-forwards that can be utilized in the future to offset taxable income.
In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the U.S. based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the North America Takeda Agreement in July 2012, the Company determined that the internal transfer of the intellectual property was only partially complete and is continuing to evaluate whether the U.S. rights related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. For the year ended December 31, 2012, the Company recorded a benefit of approximately $1.9 million related to the partial reversal of the internal transfer and reduced the deferred charge and deferred tax liability by approximately $23.8 million and $24.1 million, respectively. As of December 31, 2014 and 2013, the total deferred charge is $2.0 million and $5.2 million, respectively, after a net current year amortization and impairment expense of $3.2 million and $673,000, respectively.
For all significant intercompany transactions, the Company’s management has evaluated the terms of the transactions using significant estimates and judgments to ensure that each significant transaction would be on similar terms if the Company completed the transaction with an unrelated party. Although the Company believes there will be no material tax liabilities to the Company as a result of multi-jurisdictional transactions, there can be no assurance that taxing authorities will not assert that transactions were entered into at monetary values other than fair values. If such assertions were made, the Company’s intention would be to vigorously defend its positions; however, there can be no assurance that additional liabilities may not occur as a result of any such assertions.
Uncertain Tax Positions
The Company applies the accounting guidance for uncertain tax positions that requires the application of a more likely than not threshold to the recognition and de-recognition of uncertain tax positions. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement.
The Company has recorded an income tax liability of approximately $842,000 and $679,000, including interest, for uncertain tax positions as of December 31, 2014 and 2013, respectively. As of December 31, 2014, $263,000 and $579,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. As of December 31, 2013, $42,000 and $637,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. These amounts represent the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2014 and 2013 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions. During the twelve months ended December 31, 2014, the liability for income taxes has increased by approximately $163,000. This increase in the liability is related primarily to current year activity in the U.S. and revisions to prior year estimates.
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company expects to reverse certain prior period liabilities as a result of tax periods no longer being subject to examination; therefore, the amount of $263,000 expected to reverse within the next twelve months has been recorded as a current liability. Other than this expected reversal, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits would have an effect on the effective tax rate when recognized.
Currently, tax years 2011, 2012, 2013 and 2014 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed.
Deferred Charge
Certain intellectual property was transferred within the group resulting in a gain in the sellers’ tax jurisdiction and a difference in the buyer’s tax jurisdiction between the new tax basis and the carrying amount of those assets. The Financial Accounting Standards Board (FASB) guidance on income taxes precludes the Company from including the effects of any intercompany transfers in the financial statements, and so the net tax effect of an intercompany transaction is deferred in consolidation.
These deferred tax effects include the reversal of any existing deferred tax asset (and its related valuation allowance, if any) or liability and any taxes currently payable resulting from the intercompany transaction when the asset remains in the consolidated group for financial reporting purposes. This deferred effect is not the result of a temporary difference and is therefore classified as a deferred charge on the Consolidated Balance Sheet separate from the Company's deferred tax assets.
Since the deferred charge is not part of the deferred tax assets, it is not subject to revaluation for tax rate changes and realizability as prescribed by the FASB’s guidance on income taxes. Thus, the deferred charge will remain fixed and will be amortized over the determined life of 10 years and be included as part of the provision for income taxes as a permanent difference.
Foreign Currency
The Company translates the assets and liabilities of its foreign subsidiaries into U.S. Dollars at the current exchange rate in effect at the end of the year and maintains the capital accounts of these subsidiaries at the historical exchange rates. The revenue, income and expense accounts of the foreign subsidiaries are translated into U.S. Dollars at the average rates that prevailed during the relevant period. The gains and losses that results from this process are included in accumulated other comprehensive income in the stockholders’ equity section of the balance sheet.
Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income.
Other Comprehensive Income
Comprehensive income consists of net income plus certain other items that are recorded directly to stockholders’ equity. The Company has reported comprehensive income in the Consolidated Statements of Operations and Comprehensive Income.
The Company has outstanding intercompany loans and investments between its subsidiaries which are eliminated for purposes of the Consolidated Financial Statements. These intercompany loans are not expected to be repaid or settled in the foreseeable future. Accordingly, the currency transaction gains or losses on these intercompany loans are recorded as part of other comprehensive income in the Consolidated Financial Statements. In addition, the actuarial gains and losses of the Swiss Pension plan are recorded in comprehensive income.
Recent Accounting Pronouncements
In April 2014, the FASB issued Accounting Standards Update 2014-08, “Presentation of Financial Statements and Property, Plant and Equipment”. Under the new standard, only disposals representing a strategic shift in operations that have a major effect on the organization's operations and financial results, or a business activity classified as held for sale, should be presented as discontinued operations. Additionally, it expands the disclosure requirements for discontinued operations to provide more information regarding the assets, liabilities, income and expenses of discontinued operations. This update is effective for interim and annual periods beginning after December 15, 2014, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers”. While the standard supersedes existing revenue recognition guidance, it closely aligns with current GAAP. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. The Company is currently evaluating the impact the adoption of this standard will have on the Company’s consolidated financial statements.
In August 2014, the FASB issued Accounting Standards Update 2014-15, “Presentation of Financial Statements-Going Concern”. The new standard provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is permitted. The Company is currently evaluating the impact of adopting this standard, but does not expect it will have a material impact on the Company’s consolidated financial statements.

Note_3_Net_Income_Per_Share

Note 3 - Net Income Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	3. Net Income per Share
	Basic net income per share is computed by dividing net income by the sum of the weighted average class A and class B common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.
	The computation of net income per share for the years ended December 31, 2014, 2013 and 2012 is shown below:
		YTD December 31,
	(in thousands, except per share data)	2014		2013		2012
	Basic net income per share:
	Net income	$	13,128	$	7,015	$	5,061
	Weighted average class A and B common shares outstanding		43,691		41,716		41,660
	Basic net income per share	$	0.3	$	0.17	$	0.12
	Diluted net income per share:
	Net income	$	13,128	$	7,015	$	5,061
	Weighted average class A and B common shares outstanding for diluted net income per share		43,691		41,716		41,660
	Assumed exercise of stock options under the treasury stock method		815		828		125
			44,506		42,544		41,785
	Diluted net income per share	$	0.29	$	0.16	$	0.12
	The potentially dilutive securities used in the calculations of diluted net income per share at December 31, 2014, 2013 and 2012 are as follows:
		December 31,
	(In thousands)	2014		2013		2012
	Employee stock options		1,124		2,129		2,811
	Non-employee stock options		255		410		450
	The following securities were excluded from the computation of diluted net income per share as their effect would be anti-dilutive as of December 31, 2014, 2013 and 2012:
		December 31,
	(In thousands)	2014		2013		2012
	Employee stock options		3,012		530		596

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Investment [Text Block]	4. Current and Non-Current Investments
	At December 31, 2014 and 2013, current and non-current investments consisted of the following securities:
			31-Dec-14
	(In thousands)		Cost		Unrealized		Unrealized			Fair Value
					Gains		Losses
	Current:
	U.S. government agencies		$	4,203	$	1	$	-		$	4,204
	Certificates of deposits			2,500		-		-			2,500
	Corporate bonds			4,575		-		(3	)		4,572
	U.S. commercial paper			11,109		8		-			11,117
	Total		$	22,387	$	9	$	(3	)	$	22,393
	Non-current:
	U.S. government agencies		$	8,047	$	-	$	(15	)	$	8,032
	Certificates of deposits			5,000							5,000
	Corporate bonds			509		-		(1	)		508
	Total		$	13,556	$	-	$	(16	)	$	13,540
			31-Dec-13
	(In thousands)		Cost		Unrealized		Unrealized			Fair Value
					Gains		Losses
	Current:
	U.S. government securities		$	1,000	$	-	$	-		$	1,000
	U.S. government agencies			9,048		3		-			9,051
	Certificates of deposit			3,500		-		-			3,500
	Corporate bonds			752		-		-			752
	Municipal securities			1,700		-		-			1,700
	Total		$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies		$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposit		$	2,500						$	2,500
	Corporate bonds			511		-		(1	)		510
	Total		$	7,223	$	-	$	(4	)	$	7,219
	The Company performs fair value measurements in accordance with the FASB’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:
	Level 1: quoted prices in active markets for identical assets or liabilities;
	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, are as follows:
			Fair Value Measurements at Reporting Date Using
	31-Dec-14		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)		(Level 1)		(Level 2)		(Level 3)
	U.S. government securities		$	-	$	14,850	$	-		$	14,850
	U.S. government agencies			-		12,686		-			12,686
	U.S. commercial paper			-		15,092		-			15,092
	Certificates of deposits			-		8,000		-			8,000
	Corporate bonds			-		10,181		-			10,181
	Money market funds			3,111		-		-			3,111
	Total assets measured at fair value (a)		$	3,111	$	60,809	$	-		$	63,920
	(a)	included in total assets are approximately $28.0 million of cash equivalents
			Fair Value Measurements at Reporting Date Using
	31-Dec-13		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)		(Level 1)		(Level 2)		(Level 3)
	U.S. government securities		$	-	$	1,000	$	-		$	1,000
	U.S. commercial paper			-		13,260		-			13,260
	Municipal securities			-		6,449		-			6,449
	Certificates of deposits			-		1,700		-			1,700
	Corporate bonds			-		6,000		-			6,000
	Money market funds			-		5,533		-			5,533
	Variable rate demand notes			5,955		-		-			5,955
	Total assets measured at fair value		$	5,955	$	33,942	$	-		$	39,897
	If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.
	There were no transfers between levels during the years ended December 31, 2014 and 2013.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment
	Property and equipment consists of the following at December 31, 2014 and 2013:
		December 31,
	(In thousands)	2014			2013
	Computer and office machines	$	2,622		$	2,607
	Furniture and fixtures		473			480
	Leasehold improvements		1,415			1,444
	Total cost		4,510			4,531
	Less: accumulated depreciation		(3,747	)		(3,375	)
	Total	$	763		$	1,156
	Depreciation expense for the years ended December 31, 2014, 2013 and 2012 was approximately $422,000, $512,000 and $542,000, respectively.
	The leasehold improvements as of December 31, 2014 and 2013 are tenant improvements to the Company’s headquarters in Bethesda, Maryland.

Note_6_Intangible_Assets

Note 6 - Intangible Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	6. Intangible Assets
	The Company reviews definite lived intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. The carrying value of an intangible asset is assessed for impairment whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. The amount of impairment loss recognized is the amount the carrying value exceeds its fair value.
	During the three months ended September 30, 2014 the Company ceased RESCULA direct commercialization activities and ceased marketing RESCULA for its approved FDA indication. Accordingly, the Company recorded an impairment charge of $5.6 million during the three months ended September 30, 2014 which represented the full amount of the remaining balances of the unamortized intangibles related to its two RESCULA license agreements described below. Both license agreements were for the development and commercialization of RESCULA for its approved indication and for any new indications for unoprostone isopropyl. Of the total impairment charge, $1.5 million is included in the Company’s Americas segment, and $4.1 million is included in the Company’s Europe segment for the twelve months ended December 31, 2014. There were no impairment charges recorded during the twelve months ended December 31, 2013 and 2012.
	In April 2009, the Company entered into an agreement with R-Tech (2009 R-Tech Agreement) to license all patents and other intellectual property rights related to RESCULA for its FDA approved indication and any new indications for unoprostone isopropyl in the U.S. and Canada. A sNDA for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February 2013. Under the terms of the 2009 R-Tech Agreement, the Company made upfront and milestone payments totaling $3.5 million, of which $3.4 million was allocated to an intangible asset and is included in “intangible assets, net” in the accompanying Consolidated Balance Sheet as of December 31, 2013. During the three months ended September 30, 2014, the Company ceased direct commercialization activities for RESCULA and has fully impaired the unamortized value of this intangible asset, resulting in a charge of $1.5 million. The Company had been amortizing the $3.4 million intangible over the 10-year life of the 2009 R-Tech Agreement, which the Company believed approximated the useful life of the underlying rights and data for the approved FDA indication. Amortization expense was approximately $227,000 and $341,000 for the twelve months ended December 31, 2014 and 2013, respectively. The unamortized amount included in intangible assets was nil at December 31, 2014 and $1.8 million at December 31, 2013.
	In March 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, (2011 R-Tech Agreement) expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the U.S. and Canada to the rest of the world, with the exception of the R-Tech Territory. Pursuant to the 2011 R-Tech Agreement, the Company made payments to R-Tech of $6.0 million, which is reflected in “intangible assets, net” in the accompanying Consolidated Balance Sheet as of December 31, 2013. During the three months ended September 30, 2014, the Company ceased direct commercialization activities for RESCULA and has fully impaired the unamortized value of this intangible asset, resulting in a charge of $4.1 million. The Company had been amortizing the $6.0 million intangible over the 10-year life of the 2011 R-Tech Agreement, which the Company believed approximated the useful life of the underlying rights and data for the indication previously approved in Europe. Amortization expense was approximately $409,000 and $613,000 for the twelve months ended December 31, 2014 and 2013, respectively. The unamortized amount included in intangible assets was nil at December 31, 2014 and $4.4 million at December 31, 2013.

Note_7_Accrued_Expenses

Note 7 - Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued Expenses
	Accrued expenses consist of the following at December 31, 2014 and 2013:
		December 31,
	(In thousands)	2014		2013
	Research and development costs	$	3,537	$	1,775
	Employee compensation		3,459		2,531
	Selling and marketing costs		163		584
	Legal service fees		612		14
	Other accrued expenses		696		778
	Total	$	8,467	$	5,682

Note_8_Collaboration_Obligatio

Note 8 - Collaboration Obligation	12 Months Ended
	Dec. 31, 2014
Collaboration Obligation [Abstract]
Collaboration Obligation [Text Block]	8. Collaboration Obligation
	Under the Global License Agreement (see Note 14), the Company received an upfront payment from Takeda of $14.0 million in 2014, of which the Company is obligated to reimburse Takeda for the first $6.0 million in developmental expenses incurred by Takeda.

Note_9_Other_Current_Liabiliti

Note 9 - Other Current Liabilities	12 Months Ended
	Dec. 31, 2014
Other Current Liabilities [Member]
Note 9 - Other Current Liabilities [Line Items]
Other Liabilities Disclosure [Text Block]	9. Other Current Liabilities
	Other current liabilities consist of the following at December 31, 2014 and 2013:
		December 31,
	(In thousands)	2014			2013
	Indirect taxes payable		3,075			-
	Other liabilities		543			358
	Total	$	3,618		$	358
Other Noncurrent Liabilities [Member]
Note 9 - Other Current Liabilities [Line Items]
Other Liabilities Disclosure [Text Block]	10. Other Liabilities
	Other liabilities consist of the following at December 31, 2014 and 2013:
		December 31,
	(In thousands)	2014			2013
	Deferred leasehold incentive		137			255
	Deferred rent expense		243			341
	Defined benefit obligation		977			-
	Other liabilities		579			637
	Total	$	1,936		$	1,233
	Defined benefit obligation relates to defined benefit pension plans for employees in the Company’s subsidiary in Switzerland (Swiss Plan). The Swiss Plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 1.75% in 2014 and 1.50% in 2013. Under the Swiss Plan, the Company and certain of its employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee’s contribution. Minimum employee contributions are based on the respective employee’s age, salary, and gender. As of December 31, 2014, the Swiss Plan had an unfunded net pension obligation of approximately $977,000, plan assets of approximately $1.8 million and projected benefit obligation of approximately $2.8 million. The entire liability is listed as non current because plan assets are more than enough to pay expected benefit payments over the next year. The Company recognized pension expense of $221,000 for the year ended December 31, 2014 related to the Swiss Plan.
	While the Swiss Plan originated in 2011, the Company only accounted for the Swiss Plan in accordance with ASC 715-30 Defined Benefit Plans - Pensions starting in 2014. The Company evaluated the impact of not recording the net pension obligation in the Consolidated Balance Sheet and corresponding charges in Net income and Total comprehensive income in the Statement of Operations and Comprehensive Income, and the omission of the required pension disclosures in prior years, and concluded that the effect was immaterial. The Company corrected the error in 2014 by recording an out of period adjustment to the net pension obligation liability of $366,000, with an offsetting amount in Net Income of $11,000 and Total comprehensive income of $355,000. The impact of the correction of the error in 2014 was also considered immaterial.
	The following tables provide reconciliations of the changes in the Swiss Plan’s projected benefit obligations and assets, and the assumptions used at December 31, 2014.
	Reconciliation of Projected Benefit Obligation	31-Dec-14
	(in thousands)
	Projected benefit obligation at beginning of year	$	1,708
	Service cost		191
	Interest cost		43
	Plan participants’ contributions		165
	Actuarial loss (gain)		653
	Benefits paid		83
	Expenses Paid		(8	)
	Premiums Paid		(66	)
	Projected benefit obligation at end of year	$	2,769
	Reconciliation of Fair Value of Plan Assets	31-Dec-14
	(in thousands)
	Fair value of plan assets at beginning of year	$	1,342
	Actual return on plan assets		42
	Employer contribution		234
	Plan participants’ contributions		165
	Benefits paid		83
	Expenses Paid		(8	)
	Premiums Paid		(66	)
	Fair value of plan assets at end of year	$	1,792
	Funded status at end of year	$	(977	)
	Reconciliation of amounts recognized in Consolidated Statements of Operations and Comprehensive Income	Year ended
		31-Dec-14
	(in thousands)
	Net loss	$	(978	)
	Total amount recognized in accumulated other comprehensive income	$	(978	)
	Accumulated contributions in excess of net periodic benefit cost		1
	Funded status at end of year	$	(977	)
	Net periodic pension cost included the following components	Year ended
		31-Dec-14
	(in thousands)
	Service cost	$	191
	Interest cost		43
	Expected return on assets		(30	)
	Amortization of unrecognized net loss		17
	Net periodic pension cost	$	221
	Changes in plan assets and benefit obligations recognized in other comprehensive income	Year ended
		31-Dec-14
	(in thousands)
	Net loss arising during year	$	641
	Amortization or settlement of net loss		(17	)
	Total recognized in other comprehensive income	$	624
	Total loss recognized in net periodic cost and other comprehensive income	$	845
	Estimated amounts to be amortized from accumulated other comprehensive income over the next year	31-Dec-14
	(in thousands)
	Net loss	$	73
	Additional year-end information for plans with projected benefit obligations in excess of plan assets	31-Dec-14
	(in thousands)
	Projected benefit obligation	$	2,769
	Accumulated benefit obligation		2,469
	Fair value of plan assets		1,792
Weighted average allocation of plan assets	31-Dec-14
Debt Securities		79	%
Real Estate		12	%
Other Investments		6	%
Cash		3	%
Total		100	%
Weighted average assumptions used to determine net periodic pension cost	Year ended
	31-Dec-14
Discount or settlement rates		2.5	%
Expected long-term rates of return on assets		2.1	%
Rates of increase in compensation levels		1.5	%
Weighted average assumptions used to determine future  benefit obligations	31-Dec-14
Discount rate		1	%
Rates of increase in compensation levels		1.5	%
Expected future cash flows
(in thousands)
Employee Contributions
2015	$	151
Benefit Payments
2015		145
2016		10
2017		14
2018		18
2019		23
2020-2024		494

Note_11_Commitments_and_Contin

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and Contingencies
	Operating Leases
	The Company leases office space in the U.S., Switzerland, and Japan, under operating leases through 2017. At December 31, 2014, total future minimum, non-cancelable lease payments under operating leases are as follows:
	(In thousands of U.S. dollars)	December 31,
		2014
	2015	$	1,198
	2016		1,189
	2017		244
	2018		104
	2019		-
	Total minimum lease payments	$	2,735
	Rent expense for all operating leases was $1.4 million, $1.5 million and $1.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Research and Development Costs
	The Company routinely enters into agreements with third-party CROs to oversee clinical research and development studies provided on an outsourced basis and assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs through 2017 under these agreements as of December 31, 2014 were approximately $8.5 million.
	The maximum contingent liability under the Numab Agreement (see Note 12) in the event that Numab defaults under its loan with Zurcher Kantonalbank is $2.2 million. As of December 31, 2014, the potential amount of payments in the event of Numab’s default is $2.0 million.

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12.  Related Party Transactions
	R-Tech Ueno, Ltd.
	Drs. Ryuji Ueno and Sachiko Kuno are married to each other and, directly or indirectly, own the majority of the stock of R-Tech. Drs. Ueno and Kuno are also controlling stockholders of S&R Technology Holding, LLC (S&R), which in turn is the Company’s controlling stockholder. Dr. Ueno was the Company’s Chief Executive Officer and Chairman of the Company’s Board of Directors (Board or Board of Directors) through March 3, 2014 and was our Chief Scientific Officer through March 18, 2014.
	The Company does not own manufacturing facilities for the production of commercial quantities of AMITIZA or preclinical or clinical supplies of the other prostone compounds that the Company is testing in its development programs. Instead, the Company contracts with R-Tech as the sole manufacturer of the Company’s products to produce AMITIZA, RESCULA, cobiprostone and ion channel activators and any of the Company’s future prostone compounds. The Company has entered into multiple exclusive supply arrangements with R-Tech and has granted to R-Tech the exclusive right to manufacture and supply AMITIZA and other products and compounds to the Company to meet its commercial and clinical requirements. Since 2003, the Company has received upfront, development and milestone payments under these agreements totaling $9.0 million through December 31, 2014. With the exception of the exclusive supply agreements with Takeda, R-Tech is prohibited from supplying AMITIZA to anyone other than the Company during this period. The Company’s supply arrangement with R-Tech also provides that R-Tech will assist the Company in connection with applications for marketing approval for AMITIZA, including assistance with regulatory compliance for chemistry, manufacturing and controls. Either the Company or R-Tech may terminate the supply arrangement in the event of the other party’s uncured breach or insolvency.
	The Company recorded the following expenses under all of its agreements with R-Tech for the years ended December 31, 2014, 2013 and 2012:
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Clinical supplies	$	396	$	827	$	1,450
	Other research and development services		171		194		466
	Commercial supplies		15,776		14,902		3,288
		$	16,343	$	15,923	$	5,204
	Deferred revenues under the Company’s agreements with R-Tech consist of the following at December 31, 2014 and 2013.
		Year Ended December 31,
	(In thousands)	2014		2013
	Deferred revenue, current	$	453	477
	Deferred revenue, non-current		4,141	4,925
		$	4,594	5,402
	R-Tech has a 30-year lease with Ueno Fine Chemicals Industry, LTD. (Ueno Fine Chemical) for the land on which R-Tech’s manufacturing facility that produces lubiprostone is located. There are approximately 18 years remaining on the lease and R-Tech’s manufacturing facility is on the campus of Ueno Fine Chemical. R-Tech and Ueno Fine Chemical had been in litigation in Japan over the terms of the lease, including whether or not the lease should be terminated. In December 2014 the parties resolved the dispute and R-Tech’s lease remains in effect with no expected adverse effects on the Company’s supply of lubiprostone.
	Numab AG
	In September 2011, the Company entered into the Numab Agreement with Numab. Under the terms of the Numab Agreement, which extends through September, 2016, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.2 million as of December 31, 2014.
	As of December 31, 2014, collateral of CHF 2.2 million had been deposited by the Company and Numab has utilized CHF 2.0 million of its loan facility, or approximately $2.0 million. At December 31, 2014 and 2013, the Company has a recorded guarantee liability of $1.0 million and $663,000, respectively, in collateral callable to meet a potential loan default by Numab.

Note_13_Notes_Payable

Note 13 - Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	13. Notes Payable
	In November 2010, the Company entered into a ¥1,000,000,000, approximating $11.6 million as of the closing date, secured term loan agreement with the Tokyo-Mitsubishi Bank. The loan agreement provided for the extension of credit for the period of one year that could be renewed annually upon the agreement of the Company and the Tokyo-Mitsubishi Bank. The loan agreement was not renewed in November 2014 and the outstanding loan balance was paid in full at that time. The outstanding loan balances included in the accompanying Consolidated Balance Sheets were nil and $9.5 million as of December 31, 2014 and 2013, respectively. The Company agreed to maintain an amount of collateral that would not fall below 90.0% of the initial balance throughout the term of the loan. The Company had deposited $14.9 million with the Tokyo-Mitsubishi Bank and is recorded as “restricted cash, current” in the accompanying Consolidated Balance Sheets as of December 31, 2013. The collateral was returned to the Company upon the retirement of the loan.
	In March 2013, the Company entered into a ¥1,000,000,000, approximating $10.6 million as of the closing date, secured term loan agreement with the Mizuho Bank. The loan agreement provided for the extension of credit for the period of one year, which can be renewed annually upon the agreement of the Company and the Mizuho Bank. The outstanding loan balance was paid in full during the fourth quarter of 2014. The outstanding loan balances included in the accompanying Consolidated Balance Sheets were nil and $9.5 million as of December 31, 2014 and 2013, respectively. The Company agreed to maintain an amount of collateral that would not fall below 100% of the initial balance throughout the term of the loan. The Company had deposited $11.0 million with the Mizuho Bank and is recorded as “restricted cash, current” in the accompanying Consolidated Balance Sheet as of December 31, 2013. The collateral was returned to the Company upon the retirement of the loan.
	Subordinated Unsecured Promissory Notes
	In connection with the SAG acquisition in 2010, the Company issued a subordinated unsecured promissory note (Notes) to the Ueno Trust and Kuno Trust, former shareholders of SAG. Each of the Notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the Notes is equal to the per annum rate of interest determined on the basis of the sum of London Interbank Offered Rate, or LIBOR, plus 4.0%, and will be reset every six months on December 1st and June 1st of each year. The interest rate beginning December 1, 2014 is 4.3%.
	The Notes provide for a semi-annual repayment schedule of interest and principal over a seven-year period on each June 1st and December 1st, provided that, through December 1, 2012, all accrued and unpaid interest was not paid in cash, but rather added to the principal balance of the notes. Interest paid-in-kind was nil, nil, and $2.2 million for the three years ended December 31, 2014, 2013 and 2012, respectively.
	The Notes can be prepaid at any time without penalty. In addition, the Notes provide for a mandatory prepayment (i) in full in the event of an acquisition by an unaffiliated third party in an all-cash acquisition of all of the issued and outstanding shares of capital stock of the Company or (ii) either in full or in part in certain change of control transactions involving the Company where an unaffiliated third party acquires a majority of the Company’s voting stock.
	Due to changes in LIBOR rates, the Company has estimated the fair value of the Notes payable as shown in the table below.
	The carrying value at December 31, 2014 and 2013 and the fair value at December 31, 2014 of the Notes were as follows:
		Fair Value		Carrying Value
		December 31,		December 31,
	(In thousands)	2014		2014		2013
	Loan agreements	$	-	$	-	$	19,008
	Promissory notes, Sellers of SAG		26,317		25,818		33,712
		$	26,317	$	25,818	$	52,720
	Notes payable, current			$	8,240	$	26,892
	Notes payable, non-current				17,578		25,828
				$	25,818	$	52,720
	The Company’s debt obligations are subject to the fair value disclosure requirements as discussed in Note 4 above and are classified as Level 2 securities.

Note_14_Collaboration_and_Lice

Note 14 - Collaboration and License Agreements	12 Months Ended
	Dec. 31, 2014
Collaborative And License Arrangement Disclosure [Abstract]
Collaborative And License Arrangement Disclosure [Text Block]	14. Collaboration and License Agreements
	North America Takeda Agreement
	In October 2004, we entered into an agreement with Takeda to develop and commercialize AMITIZA for gastrointestinal indications in the U.S. and Canada. The original agreement was amended on February 1, 2006 through a supplemental agreement, and in October 2014 we and Takeda and certain Takeda affiliates executed amendments to the agreement. Collectively, these are referred to as the North America Takeda Agreement. Payments to the Company under these agreements include a non-refundable upfront payment, non-refundable development and commercial milestone payments, reimbursement of certain development and co-promotion costs and product royalties.
	The Company has received a total of $160.0 million in upfront and development milestone payments through December 31, 2014 under the North America Takeda Agreement, including a $10.0 million development milestone received in the second quarter of 2013 for the first commercial sale of AMITIZA for OIC. Subject to development and acceptance of future indications, the Company is potentially entitled to receive additional development milestone and commercial milestone payments under the North America Takeda Agreement, although there can be no assurance that the Company will receive any such payments.
	The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the year ended December 31, 2014:
			Cash Received Through December 31,		Revenue Recognized for the Year Ended						Accounts Receivable for the Year Ended December 31,		Amount Deferred at December 31,
					December 31,
	(In thousands)		2014		Through 2012		2013		2014		2014 (1)		2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	2,375	$	1,199	$	147	$	147	$	-	$	882
	Research and development revenue:
	Up-front payment - remainder		$	17,624	$	17,624	$	-	$	-	$	-	$	-
	Development milestones			140,000		130,000		10,000		-		-		-
	Reimbursement of research and development expenses			123,087		106,451		10,354		7,221		939		-
	Total		$	280,711	$	254,075	$	20,354	$	7,221	$	939	$	-
	Product royalty revenue		$	335,626	$	239,327	$	52,100	$	62,775	$	18,576	$	-
	Co-promotion revenue		$	31,475	$	29,392	$	61	$	3,360	$	1,338	$	-
	(1)      Includes billed and unbilled accounts receivable.
	Upon execution of the North America Takeda Agreement, the Company was required to complete several deliverables, which Takeda was responsible to fund. The following are the required deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company relating to research and development revenue:
		·	Upon receipt of the $20.0 million upfront payment, the Company deferred approximately $2.4 million to be recognized using the time-based model over the performance period of the participation in various joint committee meetings. The Company expects its participation on all committees to continue throughout the term of the North America Takeda Agreement. During each of the years ended December 31, 2014, 2013 and 2012, the Company recognized approximately $147,000 of this deferred amount as collaboration revenue on the Consolidated Statements of Operations and Comprehensive Income.
		·	The Company granted Takeda an exclusive license of lubiprostone to co-develop, commercialize, and sell products for gastroenterology indications in the U.S. and Canada. The Company has recorded product royalty revenue of approximately $62.8 million, $52.1 million and $50.7 million for the years ended December 31, 2014, 2013 and 2012, respectively. This revenue is recorded as product royalty revenue in the Consolidated Statements of Operations and Comprehensive Income.
		·	The Company has provided development work necessary for an NDA submission to the FDA for the treatment of CIC and IBS-C indications. Takeda funded the initial $30.0 million of development costs, the Company was obligated to fund the first $20.0 million in excess of the initial $30.0 million funded by Takeda and the two parties are to equally share any required development costs in excess of $50.0 million. Although there was no defined performance period for this development work, the period to perform the work would not exceed the term of the North America Takeda Agreement. In January 2006, the Company received approval for its NDA for AMITIZA to treat CIC and completed and submitted the supplemental NDA for IBS-C to the FDA in June 2007.
	The Company initially deferred the residual amount of the $20.0 million upfront payment totaling approximately $17.6 million, development milestone payments received totaling $50.0 million, and reimbursement of the initial $30.0 million of research and development costs for the development of AMITIZA for CIC and IBS-C indications. These deferred amounts were applied towards the unit of accounting that combines the participation in the joint development committee and the development of CIC and IBS-C and was recognized over the performance period of developing the CIC and IBS-C NDA submissions. The Company completed the development of the CIC and IBS-C in June 2007 and filed a sNDA for IBS-C. This was the culmination of the performance period. In June 2007, the Company also recognized as revenue, in full, $30.0 million from Takeda upon the filing of the sNDA for AMITIZA to treat IBS-C. The Company received a $50.0 million development milestone from Takeda as a result of the FDA’s approval on April 29, 2008 of the sNDA for IBS-C in women aged 18 years and older and recognized the payment as research and development revenue during the year ended December 31, 2008.
	During 2006, the joint commercialization committee granted approval for the Company and Takeda to begin three new studies. The following are the three additional deliverables of the Company, along with the related contractual cash flows from Takeda and the associated obligations and performance period of the Company, when the three studies were agreed upon:
		·	The Company is obligated to perform studies in connection with changes to labeling for CIC. Takeda is obligated to fund 70% of the labeling studies and the Company is obligated to fund the remaining 30%. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement.
		·	The Company is obligated to perform studies for the development of an additional indication for OIC. Takeda is obligated to fund all development work up to a maximum aggregate of $50.0 million for each additional indication and $20.0 million for each new formulation. If development costs exceed these amounts, Takeda and the Company shall equally share such excess costs. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement. The Company decided to conduct one additional phase 3 efficacy studies in order to submit a sNDA for the OBD indication. In February 2012, the Company announced that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of OBD in patients with chronic, non-cancer pain, excluding those taking methadone.
		·	The Company is obligated to perform all development work necessary for phase 4 studies, for which Takeda is obligated to fund all development work. There is no defined performance period, but the performance period will not exceed the term of the North America Takeda Agreement.
	The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. As a result of the Company and Takeda agreeing to perform and fund these studies simultaneously, the Company determined that there is no objective and reliable evidence to determine the fair value for each of the studies. Accordingly, the Company has combined these three required deliverables as a single unit of accounting. All cash payments from Takeda related to these three deliverables are deferred upon receipt and recognized over the estimated performance period to complete the three studies using the time-based model.
	In 2011, the Joint Commercialization Committee (JCC) granted approval to begin studies for a liquid formulation. In addition, in 2012, the JCC granted approval for studies for a pediatric dosage. These additional deliverables are considered separate units of accounting and the Company recognizes revenue from Takeda reimbursements for these deliverables when earned.
	The reimbursement of co-promotion costs under the Supplemental Takeda Agreement expired on May 31, 2011. Co-promotion costs after May 31, 2011 were reimbursed under the Takeda Agreement. The previous reimbursement terms of the Supplemental Takeda Agreement were based on a per diem amount by the number of our sales representatives in the field promoting AMITIZA. After May 2011, the Company was reimbursed on actual details presented to health care prescribers. The Company has recognized approximately $3.4 million, $61,000 and $3.6 million of revenues for the years ended December 31, 2014, 2013 and 2012, respectively, reflecting these co-promotion reimbursements, which is recorded as co-promotion revenue in the Consolidated Statements of Operations and Comprehensive Income (Loss).
	The Company has assessed these required deliverables to determine which deliverables are considered separate units of accounting. The Company determined that its sales force and miscellaneous marketing activities are treated as separate units of accounting. The Company is recognizing the cost reimbursements received for these deliverables as co-promotion revenues when services are performed and the reimbursement payments are due under the Supplemental Takeda Agreement.
	Global License Agreement
	On October 17, 2014, the Company and Takeda entered into the Global License Agreement to develop and commercialize AMITIZA. The territories excluded from the Global License Agreement are Canada, the U.S., Japan and the People’s Republic of China. Canada and the U.S. are covered by the North America Takeda Agreement, and Japan is covered by the Japan Abbott Agreement. Switzerland and the U.K. have already received regulatory approval for AMITZA to be marketed and sold. All other territories covered under the Global License Agreement will need to have regulatory approval before AMITZA can be sold.
	Under the terms of the Global License Agreement, the Company will supply Takeda with AMITIZA (purchased from a related party, R-Tech) at a negotiated supply price. The Company also received a nonrefundable upfront payment of $14.0 million from Takeda for exclusive rights to develop and commercialize AMITIZA in the global markets covered by the Global License Agreement. In addition, the Company is also eligible for up to $35.0 million in additional commercial milestone payments contingent on the achievement of certain net sales revenue targets. Takeda will be responsible for all development activities and costs, except that the Company will assume responsibility for the first $6.0 million of those development expenses incurred by Takeda.
	The Global License Agreement is considered a multiple-element arrangement for accounting purposes. The Company identified the rights to use the Company’s license to develop and commercialize AMITIZA and the sale of AMITIZA product at a negotiated price as the deliverables. During the fourth quarter of 2014, the Company received a $14.0 million milestone payment and allocated $8.0 million to the right to use the license and $6.0 million to a collaboration obligation to reimburse Takeda for the first $6.0 million in developmental expenses incurred. There were no product sales to Takeda under the Global License Agreement during 2014.
	Japan Abbott Agreement
	In February 2009, the Company entered into the Japan Abbott Agreement to develop and commercialize lubiprostone for the treatment of CIC in Japan. The agreement grants Abbott the right of exclusive negotiation to any additional indications for which lubiprostone is developed in Japan under all relevant patents, know-how and trademarks. Under the terms of the Japan Abbott Agreement, payments to the Company include sales of product at a negotiated sales price, a non-refundable upfront payment and non-refundable development and commercial milestone payments based on achieving specified development, regulatory and sales goals.
	The collaboration efforts under the agreement are governed by two committees consisting of an equal number of representatives from both parties. The joint commercialization and steering committee oversees commercialization-related activities and resolves any conflicts arising from a joint development committee, which oversees the development-related activities in Japan.
	The Company is required to fund and complete all the development work including additional clinical studies required to obtain regulatory approval for the treatment of CIC in Japan. The Company completed all development activities in the fourth quarter of 2012. The Company owns all the rights covered under the regulatory filings.
	Abbott is required to fund and undertake all commercialization efforts including pre-launch and post-launch marketing, promotion and distribution. Abbott is required to maintain the number of sales staff and the estimated level of annual net sales based on the commercialization plan to be developed and approved by the joint commercialization and steering committee described above.
	The Company has recorded product sales revenue under the Japan Abbott Agreement of approximately $32.1 million, which includes a $2.5 million net sales milestone, and $15.8 million for the years ended December 31, 2014 and 2013, respectively. As of December 31, 2014, the Company has received a total of $37.5 million in up-front and development milestone payments under the Japan Abbott Agreement, including most recently a $15.0 million development milestone payment received in December 2012 for the first commercial sale of AMITIZA in Japan. Under the Japan Abbott Agreement, the Company could receive additional milestone payments based on achieving other specified development and commercialization goals although there can be no assurance that the Company will receive any such payments.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Abbott Agreement for the year ended December 31, 2014:
			Cash Received		Revenue Recognized for the Year Ended						Accounts		Foreign			Amount
			Through		December 31,						Receivable		Currency			Deferred at
			December 31,								for the Year Ended					December 31,
											December 31,
	(In thousands)		2014		Through 2012		2013		2014		2014		Effects			2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	846	$	189	$	52	$	39	$	-	$	113		$	453
	Research and development revenue
	Up-front payment - remainder		$	9,154	$	9,302	$	-	$	-	$	-	$	(148	)	$	-
	Development milestone payment			27,500		27,755		-		-		-		(255	)		-
	Total		$	36,654	$	37,057	$	-	$	-	$	-	$	(403	)	$	-
	Product sales revenue		$	50,902	$	5,023	$	15,807	$	32,088	$	1,980	$	(36	)	$	-

Note_15_Stockholders_Equity

Note 15 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	15. Stockholders’ Equity
	Capital Structure
	The Company has two classes of common stock authorized; class A common stock and class B common stock. In 2012, the company’s majority stockholder and only holder of the Company’s class B common stock converted all of its outstanding shares of class B common stock into shares of the Company’s class A common stock. The Company is not authorized to issue additional shares of class B common stock except in limited circumstances. As a result of the conversion, there is now only a single class of outstanding common stock, class A common stock, which is entitled to one vote per share.
	Cantor Sales Agreement
	In January 2013 the Company entered into a sales agreement with Cantor Fitzgerald & Co., (Cantor Sales Agreement), which enables the Company to offer and sell up to an aggregate of $20.0 million of shares of its class A common stock through Cantor Fitzgerald & Co. as the Company’s sales agent. Sales of the Company’s class A common stock under the Cantor Sales Agreement are sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (Securities Act). Cantor Fitzgerald & Co. is entitled to receive a commission of 3.0% of gross sales in connection with the sale of the Company’s class A common stock. During the year ended December 31, 2014, the Company sold an aggregate of 538,521 shares of its class A common stock, and received gross proceeds of approximately $5.5 million, before deducting issuance expenses, pursuant to the Cantor sales Agreement. During the year ended December 31, 2013, the Company sold an aggregate of 749,383 shares of its class A common stock, and received gross proceeds of approximately $5.3 million, before deducting issuance expenses, pursuant to the Cantor sales Agreement.
	Treasury Stock
	On December 11, 2008, the Company announced a stock repurchase program under which the Company is authorized to purchase up to $10.0 million of its class A common stock from time to time in open-market transactions. On September 8, 2011, the  Board authorized the repurchase of up to an aggregate of $2.0 million of the Company’s class A common stock out of the $10.0 million authorized by the Board on December 9, 2008. On November 2, 2012, the Board authorized the increase of such amount of repurchase to up to an aggregate of $5.0 million. In 2014, no shares of the Company’s class A common stock were repurchased. In 2013, the Company repurchased 67,762 shares of its class A common stock under this program at a cost of $336,000. All shares of class A common stock purchased in 2013 were purchased in January, February and March of 2013.
	Stock Option Plans
	Amended and Restated 2001 Stock Incentive Plan
	In 2001, the Company adopted the 2001 Stock Incentive Plan (2001 Plan) to provide common stock incentives to certain eligible employees, officers, directors, consultants and advisors of the Company. In 2003, the Board amended the 2001 Plan (Amended 2001 Plan) to allow for a maximum of 8,500,000 shares of class A common stock to be issued under all awards. In August 2005, the Board granted 510,000 stock options to non-employees under the Amended 2001 Plan. These non-employee stock options vested immediately and have a weighted average exercise price per share of $5.85. In 2006, the Board determined no further options would be granted under the Amended 2001 Plan. Non-employee options outstanding and exercisable under the Amended 2001 Plan at December 31, 2014 and 2013 totaled 255,000 and 410,000, respectively, with a remaining contractual life of .25 and 1.33 years, respectively. Employee options outstanding and exercisable under the Amended 2001 Plan at December 31, 2014 and 2013 totaled 113,900 and 255,000, respectively, with a remaining contractual life of .93 and 2.34 years, respectively.
	A summary of the non-employee stock option activity for the year ended December 31, 2014 under the Amended 2001 Plan is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		410,000		$	5.85
	Options exercised		(155,000	)		5.85
	Options outstanding, December 31, 2014		255,000			5.85		0.25	$	2,149,650
	Options exercisable, December 31, 2014		255,000			5.85		0.25	$	2,149,650
	A summary of the employee stock option activity for the year ended December 31, 2014 under the Amended 2001 Plan is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		146,200		$	10
	Options exercised		(6,800	)		10
	Options expired		(25,500	)		10
	Options outstanding, December 31, 2014		113,900			10		0.93	$	487,492
	Options exercisable, December 31, 2014		113,900			10		0.93	$	487
	2006 Stock Incentive Plan
	In 2006, the Board approved the 2006 Stock Incentive Plan, which has been amended and restated (as amended and restate, 2006 Plan), and reserved 8,500,000 shares of class A common stock for issuance under the 2006 Plan. Option awards under the 2006 Plan are generally granted with an exercise price equal to the closing market price of the Company’s stock on the date of grant. The options generally vest over four years and have a ten-year contractual term. At December 31, 2014, a total of 3,195,271 shares were available for future grants under this plan.
	The 2006 Plan includes an “evergreen” provision by which the number of shares of the Company’s class A common stock available for issuance increases automatically on the first day of each calendar year by 5.0% of the aggregate number of shares of the Company’s class A and B common stock outstanding on such date, or such lesser number as the Board may determine. The 2006 Plan also provides that the number of shares of class A common stock included in each annual increase will be 500,000, or such lesser number as the Board may determine. The Board determined that the amount of the increase in the shares available for issuance under the 2006 Plan as of January 1, 2013 and 2014 pursuant to the “evergreen” provision was zero.
	A summary of the employee stock option activity for the year ended December 31, 2014 under the 2006 Plan is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		2,513,063		$	5.03
	Options granted		2,703,995			7.68
	Options exercised		(618,377	)		4.54
	Options forfeited		(383,915	)		4.72
	Options expired		(193,275	)		4.81
	Options outstanding, December 31, 2014		4,021,491			6.93		8.57	$	29,560,979
	Options exercisable, December 31, 2014		937,765			6.02		6.08	$	7,746,764
	During 2014, performance-based stock options granted to the Company’s Chief Executive Officer totaled 200,000 and vest when the Company’s stock price meets or exceeds $16.00 over a continuous 30 day trading period. These options expire on the four year anniversary of the grant if not vested at that time, and if vested, expire on July 30, 2028. The Company used a Monte Carlo approach and a Geometric Brownian Motion stock-pricing model to estimate the fair value of these options. During 2014, the Company also granted time-based stock options to all eligible employees. For certain eligible employees, the granted stock options had accelerated vesting conditions. Those accelerated-vesting conditions applied to 450,000 stock options and cliff vest after four years, but one third of the total award may vest each time certain pre-determined strategic objectives of the Company have been met. The granted stock options expire ten years from date of grant, and the Company used a Black-Scholes option-pricing model to estimate the fair value of these options. Time-based stock options granted totaled 2,053,245 and vest in equal annual installments over four years from date of grant and expire ten years from date of grant.
	The weighted average grant date fair value of options granted during the years ended December 31, 2014, 2013 and 2012 were $7.68, $7.36, and $6.30, respectively. As of December 31, 2014, approximately $7.6 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 3.4 years. When an option is exercised, the Company issues a new share of class A common stock. In one instance an exercise was net share settled whereby 69,499 options were exercised but only 32,870 shares were issued by the Company.
	Employee Stock Purchase Plan
	In 2006, the Board approved a 2006 Employee Stock Purchase Plan (ESPP) and reserved 4,250,000 shares of class A common stock for issuance under the ESPP. As of December 31, 2014, the Board has approved 500,000 shares of class A common stock for the ESPP. The ESPP is non-compensatory and is intended to qualify as an Employee Stock Purchase Plan as defined in Section 423 of the Internal Revenue Code of 1986, as amended. Under the ESPP, eligible employees may purchase common stock through payroll deductions of up to 10.0% of compensation during the plan period. On January 19, 2015, the Compensation Committee of the Board approved the change in the purchase price to 85.0% of market price at the end of each plan period, which is generally three months. A total of 5,853, 3,625 and 3,550 shares of common stock were purchased under the ESPP during the years ended December 31, 2014, 2013 and 2012, respectively. The Company received approximately $35,000, $24,000, and $20,000 upon purchase of shares under the ESPP for the years ended December 31, 2014, 2013 and 2012, respectively.
	Tax Benefits
	As of December 31, 2014, the balance of the Company's additional paid-in capital pool related to tax windfall benefits from the stock option exercises was $325,000.
	The Company applies a with-and-without approach in determining its intra-period allocation of tax expense or benefit attributable to stock based compensation deductions. Since the Company does not have any net operating loss carry-forwards in the U.S., the tax benefit reduces income taxes payable in the current year and is therefore recorded to additional paid-in-capital.

Note_16_Income_Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	16. Income Taxes
	Income (loss) before income taxes for the years ended December 31, 2014, 2013 and 2012 is as follows:
		Year Ending December 31,
		2014			2013			2012
	U.S.	$	18,005		$	9,175		$	8,580
	Foreign		9,128			1,768			(603	)
		$	27,133		$	10,943		$	7,977
	The provision (benefit) for income taxes consists of the following for the years ended December 31, 2014, 2013 and 2012:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Current tax provision (benefit):
	U.S. Federal	$	11,319		$	5,198		$	1,431
	U.S. State		1,351			1,008			658
	Foreign		793			(582	)		51
	Total current tax provision (benefit)		13,463			5,624			2,140
	Deferred provision (benefit):
	U.S. Federal		(172	)		(1,783	)		1,248
	U.S. State		(16	)		(279	)		(193	)
	Foreign		730			366			(279	)
	Total deferred provision (benefit)		542			(1,696	)		776
	Total income tax provision (benefit)	$	14,005		$	3,928		$	2,916
	Deferred tax assets (liabilities), net, consist of the following as of December 31, 2014 and 2013:
		December 31,
		2014			2013
	(In thousands)
	Deferred tax assets:
	Foreign net operating loss carry-forwards	$	1,409		$	2,538
	State net operating loss carry-forwards		3			38
	Deferred revenue		1,803			2,143
	Accrued expenses		734			1,637
	Tax benefits on stock options		2,063			2,378
	Inventory		615			1,243
	Property and equipment		15			-
	Other		207			220
	Gross deferred tax assets		6,849			10,197
	Deferred tax liabilities:
	Property and equipment		(122	)		(202	)
	Intangibles		(4,368	)		(7,070	)
	Gross deferred tax liabilities		(4,490	)		(7,272	)
	Less: valuation allowance		(2,132	)		(1,751	)
	Net deferred tax assets (liabilities)	$	227		$	1,174
	The provision (benefit) for income taxes vary from the income taxes provided based on the federal statutory rate as follows for the three years ended December 31, 2014, 2013 and 2012:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Federal tax provision (benefit)		35	%		35	%		34	%
	State taxes, net of federal tax benefit		2.1	%		4.9	%		7.3	%
	General business credits		0	%		0	%		-0.5	%
	Changes in valuation allowance		1.4	%		-21.6	%		-3.9	%
	Nondeductible expenses		1.7	%		1.3	%		1.6	%
	Stock based compensation		-0.1	%		-2.8	%		12.3	%
	Impact of intangible transfer		5.8	%		7.3	%		-18	%
	Impact of uncertain tax positions		-0.2	%		-0.1	%		-4.1	%
	Adjustment to deferred tax asset		0.5	%		11.1	%		-10.1	%
	Impact of foreign operations		-3.7	%		0.3	%		5.7	%
	Subpart F income		9.1	%		0	%		0	%
	Change in tax rates		0	%		0.6	%		12	%
	Changes in other tax matters		0	%		-0.1	%		0.3	%
			51.6	%		35.9	%		36.6	%
	At December 31, 2014 and 2013, the Company had foreign net operating loss carry-forwards of $5.9 million and $11.9 million, respectively. Approximately $1.4 million of the foreign NOLs begin to expire in December 2019, and $4.5 million of the foreign NOLs do not expire. As of December 31, 2014 and 2013, the Company had no NOLs in the U.S.
	As of December 31, 2014 and 2013, the Company had a valuation allowance on its deferred tax assets of $2.1 million and $1.8 million, respectively. The net increase in the valuation allowance of $381,000 was due to additional NOLs in foreign jurisdictions where management believes that it is more likely than not that a portion of the NOL balance will expire prior to utilization and due to other deferred tax assets generated in the period for which a valuation allowance was provided.
	In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the U.S. based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the North America Takeda Agreement in July 2012, the Company determined that the internal transfer of the intellectual property was only partially complete and is continuing to evaluate whether the U.S. rights related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. For the year ended December 31, 2012, the Company recorded a benefit of approximately $1.9 million related to the partial reversal of the internal transfer and reduced the deferred charge and deferred tax liability by approximately, $23.8 million and $24.1 million respectively. As of December 31, 2014 and 2013, the total deferred charge is $2.0 million and $5.2 million, respectively, after a net current year amortization and impairment expense of $3.2 million and $673,000, respectively.
	The valuation allowance at December 31, 2014 and 2013 relates to deferred tax assets in the foreign jurisdictions. A partial valuation allowance was maintained on the deferred tax assets of the Company’s subsidiary in Japan based on management’s estimate of the NOL carry-forwards that will expire unused. The Company will continue to evaluate its valuation allowance position in each jurisdiction on a regular basis and may partially remove the valuation allowance of its foreign subsidiaries in 2015. To the extent the Company determines that all or a portion of its valuation allowance is no longer necessary, the Company will recognize an income tax benefit in the period such determination is made for the reversal of the valuation allowance. Once the valuation allowance is eliminated in whole or in part, it will not be available to offset the Company’s future tax provision.
	The Company has recorded a total income tax liability of approximately $842,000 and $679,000, including interest for uncertain tax positions as of December 31, 2014 and 2013, respectively. The Company expects to reverse $263,000 of the liability within the next twelve months and has reflected this amount as other current liabilities. The remaining $579,000 has been recorded as other liabilities in the accompanying Consolidated Balance Sheets. The amount represents the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2014 and 2013 mainly pertains to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the years ended December 31, 2014, 2013 and 2012 is as follows:
	Year Ended December 31,
	2014			2013			2012
Balance at January 1	$	550		$	979		$	1,226
Increases for tax positions taken during prior periods		(91	)		4			207
Decreases in unrecognized tax benefits related to settlements with taxing authorities		-			(467	)		(536	)
Increases for tax positions taken during current period		253			34			82
Balance at December 31	$	712		$	550		$	979
The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. During 2014, 2013 and 2012, the Company recorded approximately $1,000, $22,000 and $42,000, respectively, of interest related to uncertain tax positions. Other than the decrease related to tax years no longer subject to examination, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within the next 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits described above would have an impact on the effective tax rate.
Currently tax years 2011, 2012, 2013 and 2014 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed. The tax years 2009-2011 were examined by the U.S. tax authorities and resulted in no tax adjustments.

Note_17_Segment_Reporting

Note 17 - Segment Reporting	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17. Segment Reporting
	The Company has determined that it has three reportable segments based on the Company’s method of internal reporting, which disaggregates business by geographic location. These segments are the Americas, Europe and Asia. The Company evaluates the performance of these segments based on income (loss) from operations, as well as other factors, that depend on the development status of these geographies. Such measures include the progress of its research and development activities, collaboration and licensing efforts, commercialization activities, product sales and other factors. The reportable segments have historically derived their revenue from joint collaboration and strategic alliance agreements. Transactions between the segments consist primarily of loans and the provision of research and development services. Following is a summary of financial information by reportable geographic segment:
	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2014
	Research and development revenue	$	7,246								$	7,246
	Product royalty revenue		62,775									62,775
	Product sales revenue		741			422			32,089			33,252
	Co-promotion revenue		3,360									3,360
	Contract and collaboration revenue		566			8,212			39			8,817
	Total revenues		74,688			8,634			32,128			115,450
	Costs of goods sold		444			407			15,181			16,032
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		11,566			5,023			3,455			20,044
	Depreciation and amortization		601			460			29			1,090
	Other operating expenses		32,340			11,259			1,823			45,422
	Income (loss) from operations		28,235			(12,644	)		11,640			27,231
	Interest income		132			6			34			172
	Interest expense		(1,364	)		(9	)		(147	)		(1,520	)
	Other non-operating expense, net		44			653			553			1,250
	Income (loss) before income taxes	$	27,047		$	(11,994	)	$	12,080		$	27,133
	Capital expenditures	$	61		$	2		$	3		$	66
	As of December 31, 2014
	Property and equipment, net	$	566		$	83		$	114		$	763
	Identifiable assets, net of intercompany loans and investments	$	111,846		$	24,984		$	4,744		$	141,574
	Year Ended December 31, 2013
	Research and development revenue	$	20,354		$	-		$	-		$	20,354
	Product royalty revenue		52,100			-			-			52,100
	Product sales revenue		556			62			15,807			16,425
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		566			46			42			654
	Total revenues		73,637			108			15,849			89,594
	Cost of goods sold		3,588			15			8,799			12,402
	Research and development expenses		11,090			5,445			4,989			21,524
	Depreciation and amortization		736			716			36			1,488
	Other operating expenses		35,911			5,900			3,173			44,984
	Income (loss) from operations		22,312			(11,968	)		(1,148	)		9,196
	Interest income		112			11			1			124
	Interest expense		(1,427	)		(302	)		(165	)		(1,894	)
	Other non-operating expense, net		(14	)		(166	)		3,697			3,517
	Income (loss) before income taxes	$	20,983		$	(12,425	)	$	2,385		$	10,943
	Capital expenditures	$	40		$	105		$	23		$	168
	As of December 31, 2013
	Property and equipment, net	$	869		$	112		$	175		$	1,156
	Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,684		$	136,877
	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2012
	Research and development revenue	$	6,189		$	-		$	15,356		$	21,545
	Product royalty revenue		50,696			-			-			50,696
	Product sales revenue		-			14			5,023			5,037
	Co-promotion revenue		3,576			-			-			3,576
	Contract and collaboration revenue		565			16			52			633
	Total revenues		61,026			30			20,431			81,487
	Cost of goods sold		98			9			2,923			3,030
	Research and development expenses		7,809			9,571			3,912			21,292
	Depreciation and amortization		484			964			40			1,488
	Other operating expenses		41,410			2,993			2,957			47,360
	Income (loss) from operations		11,225			(13,507	)		10,599			8,317
	Interest income		161			16			2			179
	Interest expense		-			(2,183	)		(163	)		(2,346	)
	Other non-operating expense, net		77			(187	)		1,937			1,827
	Income (loss) before income taxes	$	11,463		$	(15,861	)	$	12,375		$	7,977
	Capital expenditures	$	401		$	3,470		$	-		$	3,871

Note_18_Quarterly_Financial_Da

Note 18 - Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	18. Quarterly Financial Data (unaudited)
		2014 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun		31-Mar
	Total revenues	$	37,757	$	31,463		$	24,069	$	22,161
	Income from operations	$	17,048	$	3,643		$	3,811	$	2,729
	Net income	$	9,283	$	1,480		$	1,610	$	755
	Net income per share:
	Basic	$	0.21	$	0.03		$	0.04	$	0.02
	Diluted	$	0.21	$	0.03		$	0.04	$	0.02
		2013 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun		31-Mar
	Total revenues	$	24,490	$	21,163		$	27,023	$	16,919
	Income (loss) from operations	$	2,679	$	(1,044	)	$	10,169	$	(2,608	)
	Net income (loss)	$	2,323	$	1,523		$	6,245	$	(3,076	)
	Net income (loss) per share:
	Basic	$	0.06	$	0.04		$	0.15	$	(0.07	)
	Diluted	$	0.05	$	0.04		$	0.15	$	(0.07	)
	Net income (loss) per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share information may not equal annual net income (loss) per share. See “Revisions to Previously Issued Financial Statements” in Note 1.

Note_19_Subsequent_Events

Note 19 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	19. Subsequent Events
	On January 16, 2015, the Board voted to increase the authorized size of the Board from eight to nine members and appointed Robert J. Spiegel, M.D., FACP to the Board as a Class II member to fill such new vacancy.
	On January 30, 2015, Andrew P. Smith was appointed as the Chief Financial Officer of the Company.
	In January 2015, the Company successfully completed the European MRP for AMITIZA for the treatment of CIC in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, Netherlands and Spain, resulting in a recommendation for marketing authorization in these markets. Ireland has notified the Company that it has approved AMITIZA for CIC.
	On February 27, 2015, Abbott and Mylan closed Mylan’s purchase of Abbott’s non-U.S. developed markets specialty and branded generics business, which included the Japan Abbott Agreement.
	On March 4, 2015, Messrs. Anthony Celeste and William Ashton advised the Board that they will not stand for election at the 2015 annual shareholder meeting and will resign effective May 28, 2015 from the Board of Directors. The Board has decided to reduce the size of the Board from nine to seven members and will determine if there is a need to increase the size of the Board in the future. In addition, to address proportionality in the classes of directors based on the classification of the Board, on March 5, 2015, Robert J. Spiegel resigned as a Class II director of the Board and was immediately re-elected to the Board by unanimous vote of the Board as a Class III director.  Dr. Spiegel was not a member of any committee of the Board and will not receive any new or additional compensation as a result of his reappointment but will continue to be entitled to receive the same compensation he had received prior to his resignation.
	On March 9, 2014, the Company announced that it had received a press release from R-Tech concerning the preliminary data from the Phase III RP trial. In light of the information in that release, the Company determined not to engage in any further development of unoprostone. Under those circumstances, the Company notified R-Tech that it would rescind and return all of its rights and interests in and to the licenses for unoprostone to R-Tech. By doing such, R-Tech could find other partners for the development and commercialization of unoprostone outside of Japan.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II – Valuation and Qualifying Accounts
	(In thousands)		Balance at		Additions			Deductions				Balance at
			Beginning		Charged to							End of Year
			of Year		Costs and
					Expenses
	Allowance for doubtful accounts:
	2012		$	-	$	280	(a)	$	-			$	280
	2013		$	280	$	160	(a)	$	-			$	440
	2014		$	440	$	364	(a)	$	(779	)	(b)	$	25
	Valuation allowance for deferred tax assets:
	2012		$	4,467	$	1,073	(c)	$	(1,398	)	(c)	$	4,142
	2013		$	4,142	$	-		$	(2,391	)	(d)	$	1,751
	2014		$	1,751	$	381	(e)	$	-			$	2,132
	(a)	In 2012, 2013 and 2014, the increase in allowance for doubtful accounts is associated with certain disputed Takeda invoices.
	(b)	The 2014 deduction from allowance for doubtful accounts resulted from a charge-off of certain disputed Takeda invoices.
	(c)	In 2012, the net decrease in valuation allowance for deferred tax assets of $325,000 was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.
	(d)	In 2013, the net decrease in valuation allowance for deferred tax assets of $2.4 million was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent for anticipated liquidation.
	(e)	In 2014, the net increase of $381,000 in valuation allowance for deferred tax assets was primarily due to the additional NOL’s in foreign jurisdictions where management believes it is more likely than not a portion of the NOL balance will expire prior to utilization.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. of America, (GAAP) and the rules and regulations of the Securities and Exchange Commission, (SEC). The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: SAG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts operations in North and South America and Sucampo Pharma Europe, Ltd., based in Oxford, U.K. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Error Corrections and Prior Period Adjustments, Policy [Policy Text Block]	Revisions to Previously Issued Financial Statements
	While preparing historical financial statements for the year ended December 31, 2013 and quarters ended March 31, 2014 and June 30, 2014, the Company identified certain immaterial errors in the presentation of certain line items in the previously reported financial statements. In accordance with ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, the Company evaluated these errors and, based on an analysis of quantitative and qualitative factors, determined that they were not material, individually or in aggregate, to any previously issued financial statements and, therefore, amendment of previously filed reports with the SEC was not required. The Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings.
	The Company has revised the Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2013 and 2012, the three months March 31, 2014, and the Consolidated Balance Sheets as of December 31, 2013 and 2012 to correct errors in the recognition of indirect taxes at its Swiss subsidiary. The errors affect the years ended December 31, 2012 and 2013 and the periods ended March 31, 2013, June 30, 2013, September 30, 2013 and March 31, 2014. During those periods, the Company overstated its indirect tax liability and understated net income.
	The Company has also revised the Consolidated Statements of Cash Flows for the year ended December 31, 2013 to correct errors in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents and the change in net income. The errors in classification affect the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013. These errors have no effect on the balances of cash and cash equivalents.
	Selected Items - Annual		As				Revision				As
			Previously				Adjustment				Revised
			Reported
	Consolidated Balance Sheet
	(In thousands)		Presentation as of December 31, 2013
	Other assets		$	584			$	(96	)		$	488
	Total assets			136,973				(96	)			136,877
	Other liabilities			2,150				(917	)			1,233
	Total liabilities			78,825				(917	)			77,908
	Accumulated deficit			(27,681	)			821				(26,860	)
	Total stockholders' equity			58,148				821				58,969
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands)		Presentation as of the year ended December 31, 2012
	Other income (expense), net		$	1,602			$	225			$	1,827
	Total non-operating income (expense), net			(565	)			225				(340	)
	Income (loss) before income taxes			7,752				225				7,977
	Net income			4,836				225				5,061
	Comprehensive income			3,148				225				3,373
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands, except per share data)		Presentation as of the year ended December 31, 2013
	Other income (expense), net		$	2,921			$	596			$	3,517
	Total non-operating income (expense), net			1,151				596				1,747
	Income (loss) before income taxes			10,347				596				10,943
	Net income			6,419				596				7,015
	Net income per share: Basic			0.15				0.02				0.17
	Net income per share: Diluted			0.15				0.01				0.16
	Comprehensive income			5,854				596				6,450
	Consolidated Statements of Cash Flows
	(In thousands)		Presentation as of the year ended December 31, 2013
	Net cash provided by (used in) operating activities		$	(5,418	)		$	1,209			$	(4,209	)
	Net cash provided by (used in) investing activities			(13,881	)			1,265				(12,616	)
	Effect of exchange rates on cash and cash equivalents			798				(2,474	)			(1,676	)
	Selected Items - Quarterly		As				Revision				As
			Previously				Adjustment				Revised
			Reported
	Consolidated Balance Sheet
	(In thousands)		Presentation as of March 31, 2014
	Other Assets		$	455			$	28			$	483
	Other liabilities			1,596				(917	)			679
	Total liabilities			78,839				(917	)			77,922
	Accumulated deficit			(27,006	)			945				(26,061	)
	Total stockholders' equity			65,406				945				66,351
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands)		Presentation as of the three months ended March 31, 2014
	Other income (expense), net		$	(323	)		$	124			$	(199	)
	Total non-operating income (expense), net			(666	)			124				(542	)
	Income (loss) before income taxes			1,939				124				2,063
	Income tax benefit (provision)			(1,264	)			(44	)			(1,308	)
	Net income			675				80				755
	Comprehensive income			564				80				644
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	For the purpose of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity of 90 days or less at the time of purchase.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash
	Restricted cash at December 31, 2014 primarily represented collateral pledged to support a loan guarantee and development agreement (Numab Agreement) between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $2.4 million at December 31, 2014.
	Restricted cash at December 31, 2013 primarily represented collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd. (Tokyo-Mitsubishi Bank); a loan agreement with The Mizuho Bank, Ltd. (Mizuho Bank); the Numab Agreement, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at December 31, 2013.
Investment, Policy [Policy Text Block]	Current and Non-Current Investments
	Current and non-current investments consist primarily of U.S. government agency securities, certificates of deposit, corporate bonds, municipal securities and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available-for-sale securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of December 31, 2014 and 2013, approximately $37.0 million, or 33.6%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or U.S. government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 71.3%, 81.3% and 74.4% of the Company’s total revenues for the years ended December 31, 2014, 2013 and 2012, respectively. Accounts receivable and product royalties receivable from Takeda accounted for 88.5% and 88.2% of the Company’s total accounts receivable and product royalties receivable at December 31, 2014 and 2013. Revenues from another unrelated party, Abbott, accounted for 27.8%, 17.6% and 19.3% of the Company’s total revenues for the years ended December 31, 2014, 2013 and 2012. The Company depends significantly upon collaborations with Takeda and Abbott, and its activities may be impacted if these relationships are disrupted (see Note 14).
	The Company has an exclusive supply arrangement with R-Tech to provide the Company with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations (see Note 12).
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the Notes (as defined below) payable at December 31, 2014 and 2013 were less than the estimated fair values (see Note 13.) The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable
	Accounts receivable primarily represents amounts due under the North America Takeda Agreement and Japan Abbott Agreement. The Company recorded an allowance for doubtful accounts of approximately $25,000 and $440,000 at December 31, 2014 and 2013, respectively, related to certain disputed Takeda invoices. Accounts receivable of approximately $779,000 was charged off against the allowance for doubtful accounts during the year ended December 31, 2014.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment are recorded at cost and consist of computer and office machines, furniture and fixtures, and leasehold improvements. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer and office machines are depreciated over four years and furniture and fixtures are depreciated over seven years. Leasehold improvements are amortized over the shorter of ten years or the life of the lease. Significant additions and improvements are capitalized. Expenditures for maintenance and repairs are charged to earnings as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in earnings.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment Evaluation for Long-lived Assets
	The Company reviews definite lived intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. The carrying value of an intangible asset is assessed for impairment whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. The amount of impairment loss recognized is the amount the carrying value exceeds its fair value (see Note 6).
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company’s revenues are derived primarily from product royalties, product sales, development milestone payments, clinical development activities, contract and collaboration activities,].
	Multiple-Element Arrangements
	The Company evaluated the multiple deliverables within the AMITIZA agreements in accordance with the guidance of multiple deliverables under ASC 605-25 to determine whether the deliverables can be separated for revenue recognition purposes. The separation criteria include whether the deliverables have standalone value and whether objective reliable evidence of fair value exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. The Company’s deliverables under AMITIZA agreements are more fully described in Note 14 below.
	Where agreements include contingent milestones the Company evaluates whether each milestone is substantive. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. Where milestones are not considered substantive their treatment is based on either a time-based or proportional performance model.
	Research and Development Revenue
	The Company applied a time-based model of revenue recognition for cash flows associated with research and development deliverables agreed upon prior to January 1, 2011 under the North America Takeda Agreement. Under this model, cash flow streams related to each unit of accounting are recognized as revenue over the estimated performance period. Upon receipt of cash payments, such as development milestones, revenue is recognized to the extent the accumulated service time has occurred. The remainder is deferred and recognized as revenue ratably over the remaining estimated performance period.
	For research and development deliverables agreed upon subsequent to January 1, 2011 which are reimbursable by Takeda at contractually predetermined percentages, the Company recognizes revenue when the underlying research and development expenses are incurred, assuming all other revenue recognition criteria are met.
	Product Royalty Revenue
	Product royalty revenue represents royalty revenue earned on net sales of AMITIZA under the North America Takeda Agreement, and is recorded on an accrual basis when earned in accordance with contractual terms, collectability is reasonably assured and all other revenue recognition criteria are met.
	Product Sales Revenue
	Product sales revenue consists of AMITIZA sales under the Japan Abbott Agreement, the Global License Agreement, and prior to the Global License Agreement, by the Company in Europe, and RESCULA sales by the Company in the U.S. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return. There have been no product sales as of December 31, 2014 under the Global License Agreement.
	RESCULA product sales consist of RESCULA sales in the U.S. The Company recognizes revenue from RESCULA product sales less deductions for estimated sales discounts and sales returns. Revenue from product sales of RESCULA is recognized when persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and collectability is reasonably assured. The Company accounts for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product prior to and up to 12 months subsequent to the product’s labeled expiration date. As a result, the Company estimates an accrual for product returns, which is recorded as a reduction of product sales. Given the Company’s limited history of selling RESCULA and the return period, the Company cannot reasonably estimate product returns from the wholesale distribution channel. Therefore, the Company is deferring the recognition of revenue until there is confirmation of pull-through sales to end-user customers. The Company has ceased marketing RESCULA during the third quarter of 2014 and all remaining inventory is set to expire during March 2015.
	The Company’s three largest wholesale customers accounted for 89.0% and 96.2% of its RESCULA product sales for the years ended December 31, 2014 and 2013, respectively.
	Co-promotion Revenue
	Takeda reimbursements of co-promotion costs under the North America Takeda Agreement, including costs associated with the Company’s specialty sales force and miscellaneous marketing activities, are recognized as co-promotion revenue as the related costs are incurred and Takeda becomes contractually obligated to pay the amounts. We have determined that we are acting as a principal under this agreement, and as such, we record reimbursements of these amounts on a gross basis as co-promotion revenue. In December 2014, as a result of the amendment to the North America Takeda Agreement, we ceased co-promoting AMITIZA.
	Contract and Collaboration Revenue
	Contract and Collaboration revenue relates to development and consulting activities and includes $8.0 million of the upfront payment received from Takeda in 2014 under the Global License Agreement.
	The Company considers its participation in joint committees under the Japan Abbott Agreement and North America Takeda Agreement as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts.
	Deferred Revenue
	Deferred revenue represents payments received for licensing fees, option fees, consulting, research and development contracts and related cost sharing and supply agreements, mainly with Takeda, Abbott and R-Tech, which are deferred until revenue can be recognized under the Company’s revenue recognition policy. Deferred revenue also includes product sales of RESCULA that are deferred until the product is sold to end-user customers or until wholesale customers return the product to the Company. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within 12 months of the balance sheet date. At December 31, 2014 and 2013, total deferred revenue was approximately $7.2 million and $7.5 million, respectively.
	Total deferred revenue consists of the following as of:
			December 31,
	(In thousands)		2014				2013
	Deferred revenue, current		$	2,051			$	1,365
	Deferred revenue, non-current			5,118				6,169
			$	7,169			$	7,534
	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current		$	453			$	477
	Deferred revenue to related parties, non-current			4,141				4,925
	Total		$	4,594			$	5,402
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses from third parties who conduct research and development activities pursuant to development and consulting agreements on behalf of the Company. Costs related to the acquisition of intellectual property are expensed as incurred in research and development expenses since the underlying technology associated with such acquisitions is unproven, has not received regulatory approval at its early stage of development and does not have alternative future uses. Milestone payments due under agreements with third party contract research organizations (CROs) are accrued when it is considered probable that the milestone event will be achieved.
Accrued Research and Development Expenses [Policy Text Block]	Accrued Research and Development ExpensesAs part of the process of preparing Consolidated Financial Statements, the Company is required to estimate accruals for research and development expenses. This process involves reviewing and identifying services which have been performed by third parties on the Company’s behalf and determining the value of these services. In addition, the Company makes estimates of costs incurred to date but not yet invoiced, in relation to external CROs and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment; invoices received and contracted costs, when evaluating the adequacy of the accrued liabilities for research and development. The Company makes significant judgments and estimates in determining the accrued balance in any accounting period. No material adjustments have been required for this accrual during the years ended December 31, 2014 and 2013.
Compensation Related Costs, Policy [Policy Text Block]	Employee Stock-Based Compensation
	The Company’s determination of fair value of share-based awards on the date of grant using an option-pricing model is affected by the Company’s stock price and assumptions regarding several subjective variables. The assumptions used to estimate the fair value of stock options granted for the years ended December 31, 2014, 2013 and 2012 were as follows:
		Year Ended December 31,
		2014				2013				2012
	Expected volatility	70%	-	72%		65%	-	75%		62%	-	64%
	Risk-free interest rate	1.63%	-	2.01%		1.23%	-	1.40%		0.76%	-	1.60%
	Expected term (in years)	5.28	-	6.25		5.5	-	6.25		5.5	-	6.25
	Expected dividend yield		0%				0%				0%
	Expected Volatility: expected volatility is calculated using the Company’s historical stock prices.
	Risk-Free Interest Rate: the risk-free interest rate is based on the market yield currently available on U.S. Treasury securities with a maturity that approximates the expected term of the share-based awards.
	Expected Term: the Company elected to use the “simplified” method to calculate the expected term of share-based awards. The Company has used a lattice based model to determine the expected term for market condition share-based awards.
	Expected Dividend Yield: the Company has not paid, and does not anticipate paying, any dividends in the foreseeable future.
	Employee stock-based compensation expense for the years ended December 31, 2014, 2013 and 2012 has been reduced for estimated forfeitures as such expense is based upon awards expected to ultimately vest. Accounting guidance on share-based payments requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the years ended December 31, 2014, 2013 and 2012, the estimated forfeiture rate ranged from 10.0% to 30.94%.
	Employee stock-based compensation expense recorded in the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2014, 2013 and 2012 was as follows:
			Year Ended December 31,
	(In thousands)		2014				2013				2012
	Research and development expense		$	349			$	293			$	535
	General and administrative expense			1,816				1,260				1,349
	Selling and marketing expense			122				191				349
	Total			2,287				1,744				2,233
	Employee stock-based compensation expense per basic and diluted share of common stock		$	0.05			$	0.04			$	0.05
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company accounts for income taxes under the asset and liability method in accordance with the relevant accounting guidance for income taxes. Under the asset and liability method, the current income tax provision or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in the income tax provision during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss (NOL) carry-forwards that can be utilized in the future to offset taxable income.
	In September 2011, the Company internally transferred certain intellectual property and licenses from the Company’s subsidiaries, including the U.S. based subsidiary, to SAG. Since the transfer of these assets was to a related party, the recognition of a deferred tax asset by SAG is prohibited and the net tax effect of the transaction is deferred in consolidation. The tax liability generated from this transaction is offset by a deferred charge that is being amortized over ten years. Following the decision of the International Court of Arbitration of the International Chamber of Commerce on the North America Takeda Agreement in July 2012, the Company determined that the internal transfer of the intellectual property was only partially complete and is continuing to evaluate whether the U.S. rights related to AMITIZA will transfer to SAG in the future. This resulted in a reassessment of the deferred charge, deferred tax liability and the mix of profits and losses earned in each jurisdiction. For the year ended December 31, 2012, the Company recorded a benefit of approximately $1.9 million related to the partial reversal of the internal transfer and reduced the deferred charge and deferred tax liability by approximately $23.8 million and $24.1 million, respectively. As of December 31, 2014 and 2013, the total deferred charge is $2.0 million and $5.2 million, respectively, after a net current year amortization and impairment expense of $3.2 million and $673,000, respectively.
	For all significant intercompany transactions, the Company’s management has evaluated the terms of the transactions using significant estimates and judgments to ensure that each significant transaction would be on similar terms if the Company completed the transaction with an unrelated party. Although the Company believes there will be no material tax liabilities to the Company as a result of multi-jurisdictional transactions, there can be no assurance that taxing authorities will not assert that transactions were entered into at monetary values other than fair values. If such assertions were made, the Company’s intention would be to vigorously defend its positions; however, there can be no assurance that additional liabilities may not occur as a result of any such assertions.
Income Tax Uncertainties, Policy [Policy Text Block]	Uncertain Tax Positions
	The Company applies the accounting guidance for uncertain tax positions that requires the application of a more likely than not threshold to the recognition and de-recognition of uncertain tax positions. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that, in its judgment, is more than 50% likely to be realized upon settlement.
	The Company has recorded an income tax liability of approximately $842,000 and $679,000, including interest, for uncertain tax positions as of December 31, 2014 and 2013, respectively. As of December 31, 2014, $263,000 and $579,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. As of December 31, 2013, $42,000 and $637,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Consolidated Balance Sheets. These amounts represent the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Consolidated Financial Statements. The liability for uncertain tax positions as of December 31, 2014 and 2013 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes, as well as uncertain tax positions related to related party interest in foreign jurisdictions. During the twelve months ended December 31, 2014, the liability for income taxes has increased by approximately $163,000. This increase in the liability is related primarily to current year activity in the U.S. and revisions to prior year estimates.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company expects to reverse certain prior period liabilities as a result of tax periods no longer being subject to examination; therefore, the amount of $263,000 expected to reverse within the next twelve months has been recorded as a current liability. Other than this expected reversal, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits would have an effect on the effective tax rate when recognized.
	Currently, tax years 2011, 2012, 2013 and 2014 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed.
Deferred Charges, Policy [Policy Text Block]	Deferred Charge
	Certain intellectual property was transferred within the group resulting in a gain in the sellers’ tax jurisdiction and a difference in the buyer’s tax jurisdiction between the new tax basis and the carrying amount of those assets. The Financial Accounting Standards Board (FASB) guidance on income taxes precludes the Company from including the effects of any intercompany transfers in the financial statements, and so the net tax effect of an intercompany transaction is deferred in consolidation.
	These deferred tax effects include the reversal of any existing deferred tax asset (and its related valuation allowance, if any) or liability and any taxes currently payable resulting from the intercompany transaction when the asset remains in the consolidated group for financial reporting purposes. This deferred effect is not the result of a temporary difference and is therefore classified as a deferred charge on the Consolidated Balance Sheet separate from the Company's deferred tax assets.
	Since the deferred charge is not part of the deferred tax assets, it is not subject to revaluation for tax rate changes and realizability as prescribed by the FASB’s guidance on income taxes. Thus, the deferred charge will remain fixed and will be amortized over the determined life of 10 years and be included as part of the provision for income taxes as a permanent difference.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency
	The Company translates the assets and liabilities of its foreign subsidiaries into U.S. Dollars at the current exchange rate in effect at the end of the year and maintains the capital accounts of these subsidiaries at the historical exchange rates. The revenue, income and expense accounts of the foreign subsidiaries are translated into U.S. Dollars at the average rates that prevailed during the relevant period. The gains and losses that results from this process are included in accumulated other comprehensive income in the stockholders’ equity section of the balance sheet.
	Realized and unrealized foreign currency gains or losses on assets and liabilities denominated in a currency other than the functional currency are included in net income.
Comprehensive Income, Policy [Policy Text Block]	Other Comprehensive Income
	Comprehensive income consists of net income plus certain other items that are recorded directly to stockholders’ equity. The Company has reported comprehensive income in the Consolidated Statements of Operations and Comprehensive Income.
	The Company has outstanding intercompany loans and investments between its subsidiaries which are eliminated for purposes of the Consolidated Financial Statements. These intercompany loans are not expected to be repaid or settled in the foreseeable future. Accordingly, the currency transaction gains or losses on these intercompany loans are recorded as part of other comprehensive income in the Consolidated Financial Statements. In addition, the actuarial gains and losses of the Swiss Pension plan are recorded in comprehensive income.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In April 2014, the FASB issued Accounting Standards Update 2014-08, “Presentation of Financial Statements and Property, Plant and Equipment”. Under the new standard, only disposals representing a strategic shift in operations that have a major effect on the organization's operations and financial results, or a business activity classified as held for sale, should be presented as discontinued operations. Additionally, it expands the disclosure requirements for discontinued operations to provide more information regarding the assets, liabilities, income and expenses of discontinued operations. This update is effective for interim and annual periods beginning after December 15, 2014, and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers”. While the standard supersedes existing revenue recognition guidance, it closely aligns with current GAAP. Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. It is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is not permitted. Entities may use a full retrospective approach or report the cumulative effect as of the date of adoption. The Company is currently evaluating the impact the adoption of this standard will have on the Company’s consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, “Presentation of Financial Statements-Going Concern”. The new standard provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2016, including interim reporting periods, and early adoption is permitted. The Company is currently evaluating the impact of adopting this standard, but does not expect it will have a material impact on the Company’s consolidated financial statements.

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Selected Items - Annual	As			Revision			As
		Previously			Adjustment			Revised
		Reported
	Consolidated Balance Sheet
	(In thousands)	Presentation as of December 31, 2013
	Other assets	$	584		$	(96	)	$	488
	Total assets		136,973			(96	)		136,877
	Other liabilities		2,150			(917	)		1,233
	Total liabilities		78,825			(917	)		77,908
	Accumulated deficit		(27,681	)		821			(26,860	)
	Total stockholders' equity		58,148			821			58,969
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands)	Presentation as of the year ended December 31, 2012
	Other income (expense), net	$	1,602		$	225		$	1,827
	Total non-operating income (expense), net		(565	)		225			(340	)
	Income (loss) before income taxes		7,752			225			7,977
	Net income		4,836			225			5,061
	Comprehensive income		3,148			225			3,373
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands, except per share data)	Presentation as of the year ended December 31, 2013
	Other income (expense), net	$	2,921		$	596		$	3,517
	Total non-operating income (expense), net		1,151			596			1,747
	Income (loss) before income taxes		10,347			596			10,943
	Net income		6,419			596			7,015
	Net income per share: Basic		0.15			0.02			0.17
	Net income per share: Diluted		0.15			0.01			0.16
	Comprehensive income		5,854			596			6,450
	Consolidated Statements of Cash Flows
	(In thousands)	Presentation as of the year ended December 31, 2013
	Net cash provided by (used in) operating activities	$	(5,418	)	$	1,209		$	(4,209	)
	Net cash provided by (used in) investing activities		(13,881	)		1,265			(12,616	)
	Effect of exchange rates on cash and cash equivalents		798			(2,474	)		(1,676	)
	Selected Items - Quarterly	As			Revision			As
		Previously			Adjustment			Revised
		Reported
	Consolidated Balance Sheet
	(In thousands)	Presentation as of March 31, 2014
	Other Assets	$	455		$	28		$	483
	Other liabilities		1,596			(917	)		679
	Total liabilities		78,839			(917	)		77,922
	Accumulated deficit		(27,006	)		945			(26,061	)
	Total stockholders' equity		65,406			945			66,351
	Consolidated Statements of Operations and Comprehensive Income
	(In thousands)	Presentation as of the three months ended March 31, 2014
	Other income (expense), net	$	(323	)	$	124		$	(199	)
	Total non-operating income (expense), net		(666	)		124			(542	)
	Income (loss) before income taxes		1,939			124			2,063
	Income tax benefit (provision)		(1,264	)		(44	)		(1,308	)
	Net income		675			80			755
	Comprehensive income		564			80			644

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]			December 31,
	(In thousands)		2014			2013
	Deferred revenue, current		$	2,051		$	1,365
	Deferred revenue, non-current			5,118			6,169
			$	7,169		$	7,534
	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current		$	453		$	477
	Deferred revenue to related parties, non-current			4,141			4,925
	Total		$	4,594		$	5,402
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		Year Ended December 31,
		2014			2013			2012
	Expected volatility	70%	-	72%	65%	-	75%	62%	-	64%
	Risk-free interest rate	1.63%	-	2.01%	1.23%	-	1.40%	0.76%	-	1.60%
	Expected term (in years)	5.28	-	6.25	5.5	-	6.25	5.5	-	6.25
	Expected dividend yield		0%			0%			0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]			Year Ended December 31,
	(In thousands)		2014			2013			2012
	Research and development expense		$	349		$	293		$	535
	General and administrative expense			1,816			1,260			1,349
	Selling and marketing expense			122			191			349
	Total			2,287			1,744			2,233
	Employee stock-based compensation expense per basic and diluted share of common stock		$	0.05		$	0.04		$	0.05

Note_3_Net_Income_Per_Share_Ta

Note 3 - Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		YTD December 31,
	(in thousands, except per share data)	2014		2013		2012
	Basic net income per share:
	Net income	$	13,128	$	7,015	$	5,061
	Weighted average class A and B common shares outstanding		43,691		41,716		41,660
	Basic net income per share	$	0.3	$	0.17	$	0.12
	Diluted net income per share:
	Net income	$	13,128	$	7,015	$	5,061
	Weighted average class A and B common shares outstanding for diluted net income per share		43,691		41,716		41,660
	Assumed exercise of stock options under the treasury stock method		815		828		125
			44,506		42,544		41,785
	Diluted net income per share	$	0.29	$	0.16	$	0.12
Schedule of Potentially Dilutive Securities [Table Text Block]		December 31,
	(In thousands)	2014		2013		2012
	Employee stock options		1,124		2,129		2,811
	Non-employee stock options		255		410		450
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		December 31,
	(In thousands)	2014		2013		2012
	Employee stock options		3,012		530		596

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments Schedule [Abstract]
Available-for-sale Securities [Table Text Block]		31-Dec-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government agencies	$	4,203	$	1	$	-		$	4,204
	Certificates of deposits		2,500		-		-			2,500
	Corporate bonds		4,575		-		(3	)		4,572
	U.S. commercial paper		11,109		8		-			11,117
	Total	$	22,387	$	9	$	(3	)	$	22,393
	Non-current:
	U.S. government agencies	$	8,047	$	-	$	(15	)	$	8,032
	Certificates of deposits		5,000							5,000
	Corporate bonds		509		-		(1	)		508
	Total	$	13,556	$	-	$	(16	)	$	13,540
		31-Dec-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		9,048		3		-			9,051
	Certificates of deposit		3,500		-		-			3,500
	Corporate bonds		752		-		-			752
	Municipal securities		1,700		-		-			1,700
	Total	$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposit	$	2,500						$	2,500
	Corporate bonds		511		-		(1	)		510
	Total	$	7,223	$	-	$	(4	)	$	7,219
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Fair Value Measurements at Reporting Date Using
	31-Dec-14	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	U.S. government securities	$	-	$	14,850	$	-		$	14,850
	U.S. government agencies		-		12,686		-			12,686
	U.S. commercial paper		-		15,092		-			15,092
	Certificates of deposits		-		8,000		-			8,000
	Corporate bonds		-		10,181		-			10,181
	Money market funds		3,111		-		-			3,111
	Total assets measured at fair value (a)	$	3,111	$	60,809	$	-		$	63,920
		Fair Value Measurements at Reporting Date Using
	31-Dec-13	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. commercial paper		-		13,260		-			13,260
	Municipal securities		-		6,449		-			6,449
	Certificates of deposits		-		1,700		-			1,700
	Corporate bonds		-		6,000		-			6,000
	Money market funds		-		5,533		-			5,533
	Variable rate demand notes		5,955		-		-			5,955
	Total assets measured at fair value	$	5,955	$	33,942	$	-		$	39,897

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		December 31,
	(In thousands)	2014			2013
	Computer and office machines	$	2,622		$	2,607
	Furniture and fixtures		473			480
	Leasehold improvements		1,415			1,444
	Total cost		4,510			4,531
	Less: accumulated depreciation		(3,747	)		(3,375	)
	Total	$	763		$	1,156

Note_7_Accrued_Expenses_Tables

Note 7 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]		December 31,
	(In thousands)	2014		2013
	Research and development costs	$	3,537	$	1,775
	Employee compensation		3,459		2,531
	Selling and marketing costs		163		584
	Legal service fees		612		14
	Other accrued expenses		696		778
	Total	$	8,467	$	5,682

Note_9_Other_Current_Liabiliti1

Note 9 - Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Current Liabilities [Table Text Block]		December 31,
	(In thousands)	2014			2013
	Indirect taxes payable		3,075			-
	Other liabilities		543			358
	Total	$	3,618		$	358
Other Noncurrent Liabilities [Table Text Block]		December 31,
	(In thousands)	2014			2013
	Deferred leasehold incentive		137			255
	Deferred rent expense		243			341
	Defined benefit obligation		977			-
	Other liabilities		579			637
	Total	$	1,936		$	1,233
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	Reconciliation of Projected Benefit Obligation	31-Dec-14
	(in thousands)
	Projected benefit obligation at beginning of year	$	1,708
	Service cost		191
	Interest cost		43
	Plan participants’ contributions		165
	Actuarial loss (gain)		653
	Benefits paid		83
	Expenses Paid		(8	)
	Premiums Paid		(66	)
	Projected benefit obligation at end of year	$	2,769
	Reconciliation of Fair Value of Plan Assets	31-Dec-14
	(in thousands)
	Fair value of plan assets at beginning of year	$	1,342
	Actual return on plan assets		42
	Employer contribution		234
	Plan participants’ contributions		165
	Benefits paid		83
	Expenses Paid		(8	)
	Premiums Paid		(66	)
	Fair value of plan assets at end of year	$	1,792
	Funded status at end of year	$	(977	)
Schedule of Reconciliation of Amounts Recognized in Consolidated Statements of Operations and Comprehensive Income [Table Text Block]	Reconciliation of amounts recognized in Consolidated Statements of Operations and Comprehensive Income	Year ended
		31-Dec-14
	(in thousands)
	Net loss	$	(978	)
	Total amount recognized in accumulated other comprehensive income	$	(978	)
	Accumulated contributions in excess of net periodic benefit cost		1
	Funded status at end of year	$	(977	)
Schedule of Net Benefit Costs [Table Text Block]	Net periodic pension cost included the following components	Year ended
		31-Dec-14
	(in thousands)
	Service cost	$	191
	Interest cost		43
	Expected return on assets		(30	)
	Amortization of unrecognized net loss		17
	Net periodic pension cost	$	221
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	Changes in plan assets and benefit obligations recognized in other comprehensive income	Year ended
		31-Dec-14
	(in thousands)
	Net loss arising during year	$	641
	Amortization or settlement of net loss		(17	)
	Total recognized in other comprehensive income	$	624
	Total loss recognized in net periodic cost and other comprehensive income	$	845
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	Estimated amounts to be amortized from accumulated other comprehensive income over the next year	31-Dec-14
	(in thousands)
	Net loss	$	73
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	Additional year-end information for plans with projected benefit obligations in excess of plan assets	31-Dec-14
	(in thousands)
	Projected benefit obligation	$	2,769
	Accumulated benefit obligation		2,469
	Fair value of plan assets		1,792
Schedule of Allocation of Plan Assets [Table Text Block]	Weighted average allocation of plan assets	31-Dec-14
	Debt Securities		79	%
	Real Estate		12	%
	Other Investments		6	%
	Cash		3	%
	Total		100	%
Schedule of Assumptions Used [Table Text Block]	Weighted average assumptions used to determine net periodic pension cost	Year ended
		31-Dec-14
	Discount or settlement rates		2.5	%
	Expected long-term rates of return on assets		2.1	%
	Rates of increase in compensation levels		1.5	%
	Weighted average assumptions used to determine future  benefit obligations	31-Dec-14
	Discount rate		1	%
	Rates of increase in compensation levels		1.5	%
Schedule of Expected Benefit Payments [Table Text Block]	Expected future cash flows
	(in thousands)
	Employee Contributions
	2015	$	151
	Benefit Payments
	2015		145
	2016		10
	2017		14
	2018		18
	2019		23
	2020-2024		494

Note_11_Commitments_and_Contin1

Note 11 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(In thousands of U.S. dollars)	December 31,
		2014
	2015	$	1,198
	2016		1,189
	2017		244
	2018		104
	2019		-
	Total minimum lease payments	$	2,735

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Note 12 - Related Party Transactions (Tables) [Line Items]
Schedule of Related Party Transactions [Table Text Block]		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Clinical supplies	$	396	$	827	$	1,450
	Other research and development services		171		194		466
	Commercial supplies		15,776		14,902		3,288
		$	16,343	$	15,923	$	5,204
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		December 31,
	(In thousands)	2014		2013
	Deferred revenue, current	$	2,051	$	1,365
	Deferred revenue, non-current		5,118		6,169
		$	7,169	$	7,534
	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current	$	453	$	477
	Deferred revenue to related parties, non-current		4,141		4,925
	Total	$	4,594	$	5,402
Agreements With R-Tech [Member]
Note 12 - Related Party Transactions (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		Year Ended December 31,
	(In thousands)	2014		2013
	Deferred revenue, current	$	453	477
	Deferred revenue, non-current		4,141	4,925
		$	4,594	5,402

Note_13_Notes_Payable_Tables

Note 13 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		Fair Value		Carrying Value
		December 31,		December 31,
	(In thousands)	2014		2014		2013
	Loan agreements	$	-	$	-	$	19,008
	Promissory notes, Sellers of SAG		26,317		25,818		33,712
		$	26,317	$	25,818	$	52,720
	Notes payable, current			$	8,240	$	26,892
	Notes payable, non-current				17,578		25,828
				$	25,818	$	52,720

Note_14_Collaboration_and_Lice1

Note 14 - Collaboration and License Agreements (Tables)	12 Months Ended
	Dec. 31, 2014
Note 14 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		December 31,
	(In thousands)	2014		2013
	Deferred revenue, current	$	2,051	$	1,365
	Deferred revenue, non-current		5,118		6,169
		$	7,169	$	7,534
	Deferred revenue to related parties, included in total deferred revenue:
	Deferred revenue to related parties, current	$	453	$	477
	Deferred revenue to related parties, non-current		4,141		4,925
	Total	$	4,594	$	5,402
Takeda [Member]
Note 14 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		Cash Received Through December 31,		Revenue Recognized for the Year Ended						Accounts Receivable for the Year Ended December 31,		Amount Deferred at December 31,
				December 31,
	(In thousands)	2014		Through 2012		2013		2014		2014 (1)		2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	2,375	$	1,199	$	147	$	147	$	-	$	882
	Research and development revenue:
	Up-front payment - remainder	$	17,624	$	17,624	$	-	$	-	$	-	$	-
	Development milestones		140,000		130,000		10,000		-		-		-
	Reimbursement of research and development expenses		123,087		106,451		10,354		7,221		939		-
	Total	$	280,711	$	254,075	$	20,354	$	7,221	$	939	$	-
	Product royalty revenue	$	335,626	$	239,327	$	52,100	$	62,775	$	18,576	$	-
	Co-promotion revenue	$	31,475	$	29,392	$	61	$	3,360	$	1,338	$	-
Abbott [Member]
Note 14 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]		Cash Received		Revenue Recognized for the Year Ended						Accounts		Foreign			Amount
		Through		December 31,						Receivable		Currency			Deferred at
		December 31,								for the Year Ended					December 31,
										December 31,
	(In thousands)	2014		Through 2012		2013		2014		2014		Effects			2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	846	$	189	$	52	$	39	$	-	$	113		$	453
	Research and development revenue
	Up-front payment - remainder	$	9,154	$	9,302	$	-	$	-	$	-	$	(148	)	$	-
	Development milestone payment		27,500		27,755		-		-		-		(255	)		-
	Total	$	36,654	$	37,057	$	-	$	-	$	-	$	(403	)	$	-
	Product sales revenue	$	50,902	$	5,023	$	15,807	$	32,088	$	1,980	$	(36	)	$	-

Note_15_Stockholders_Equity_Ta

Note 15 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		410,000		$	5.85
	Options exercised		(155,000	)		5.85
	Options outstanding, December 31, 2014		255,000			5.85		0.25	$	2,149,650
	Options exercisable, December 31, 2014		255,000			5.85		0.25	$	2,149,650
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		146,200		$	10
	Options exercised		(6,800	)		10
	Options expired		(25,500	)		10
	Options outstanding, December 31, 2014		113,900			10		0.93	$	487,492
	Options exercisable, December 31, 2014		113,900			10		0.93	$	487
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2013		2,513,063		$	5.03
	Options granted		2,703,995			7.68
	Options exercised		(618,377	)		4.54
	Options forfeited		(383,915	)		4.72
	Options expired		(193,275	)		4.81
	Options outstanding, December 31, 2014		4,021,491			6.93		8.57	$	29,560,979
	Options exercisable, December 31, 2014		937,765			6.02		6.08	$	7,746,764

Note_16_Income_Taxes_Tables

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]		Year Ending December 31,
		2014			2013			2012
	U.S.	$	18,005		$	9,175		$	8,580
	Foreign		9,128			1,768			(603	)
		$	27,133		$	10,943		$	7,977
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Current tax provision (benefit):
	U.S. Federal	$	11,319		$	5,198		$	1,431
	U.S. State		1,351			1,008			658
	Foreign		793			(582	)		51
	Total current tax provision (benefit)		13,463			5,624			2,140
	Deferred provision (benefit):
	U.S. Federal		(172	)		(1,783	)		1,248
	U.S. State		(16	)		(279	)		(193	)
	Foreign		730			366			(279	)
	Total deferred provision (benefit)		542			(1,696	)		776
	Total income tax provision (benefit)	$	14,005		$	3,928		$	2,916
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
		2014			2013
	(In thousands)
	Deferred tax assets:
	Foreign net operating loss carry-forwards	$	1,409		$	2,538
	State net operating loss carry-forwards		3			38
	Deferred revenue		1,803			2,143
	Accrued expenses		734			1,637
	Tax benefits on stock options		2,063			2,378
	Inventory		615			1,243
	Property and equipment		15			-
	Other		207			220
	Gross deferred tax assets		6,849			10,197
	Deferred tax liabilities:
	Property and equipment		(122	)		(202	)
	Intangibles		(4,368	)		(7,070	)
	Gross deferred tax liabilities		(4,490	)		(7,272	)
	Less: valuation allowance		(2,132	)		(1,751	)
	Net deferred tax assets (liabilities)	$	227		$	1,174
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Federal tax provision (benefit)		35	%		35	%		34	%
	State taxes, net of federal tax benefit		2.1	%		4.9	%		7.3	%
	General business credits		0	%		0	%		-0.5	%
	Changes in valuation allowance		1.4	%		-21.6	%		-3.9	%
	Nondeductible expenses		1.7	%		1.3	%		1.6	%
	Stock based compensation		-0.1	%		-2.8	%		12.3	%
	Impact of intangible transfer		5.8	%		7.3	%		-18	%
	Impact of uncertain tax positions		-0.2	%		-0.1	%		-4.1	%
	Adjustment to deferred tax asset		0.5	%		11.1	%		-10.1	%
	Impact of foreign operations		-3.7	%		0.3	%		5.7	%
	Subpart F income		9.1	%		0	%		0	%
	Change in tax rates		0	%		0.6	%		12	%
	Changes in other tax matters		0	%		-0.1	%		0.3	%
			51.6	%		35.9	%		36.6	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		Year Ended December 31,
		2014			2013			2012
	Balance at January 1	$	550		$	979		$	1,226
	Increases for tax positions taken during prior periods		(91	)		4			207
	Decreases in unrecognized tax benefits related to settlements with taxing authorities		-			(467	)		(536	)
	Increases for tax positions taken during current period		253			34			82
	Balance at December 31	$	712		$	550		$	979

Note_17_Segment_Reporting_Tabl

Note 17 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2014
	Research and development revenue	$	7,246								$	7,246
	Product royalty revenue		62,775									62,775
	Product sales revenue		741			422			32,089			33,252
	Co-promotion revenue		3,360									3,360
	Contract and collaboration revenue		566			8,212			39			8,817
	Total revenues		74,688			8,634			32,128			115,450
	Costs of goods sold		444			407			15,181			16,032
	Intangible assets impairment		1,502			4,129			-			5,631
	Research and development expenses		11,566			5,023			3,455			20,044
	Depreciation and amortization		601			460			29			1,090
	Other operating expenses		32,340			11,259			1,823			45,422
	Income (loss) from operations		28,235			(12,644	)		11,640			27,231
	Interest income		132			6			34			172
	Interest expense		(1,364	)		(9	)		(147	)		(1,520	)
	Other non-operating expense, net		44			653			553			1,250
	Income (loss) before income taxes	$	27,047		$	(11,994	)	$	12,080		$	27,133
	Capital expenditures	$	61		$	2		$	3		$	66
	As of December 31, 2014
	Property and equipment, net	$	566		$	83		$	114		$	763
	Identifiable assets, net of intercompany loans and investments	$	111,846		$	24,984		$	4,744		$	141,574
	Year Ended December 31, 2013
	Research and development revenue	$	20,354		$	-		$	-		$	20,354
	Product royalty revenue		52,100			-			-			52,100
	Product sales revenue		556			62			15,807			16,425
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		566			46			42			654
	Total revenues		73,637			108			15,849			89,594
	Cost of goods sold		3,588			15			8,799			12,402
	Research and development expenses		11,090			5,445			4,989			21,524
	Depreciation and amortization		736			716			36			1,488
	Other operating expenses		35,911			5,900			3,173			44,984
	Income (loss) from operations		22,312			(11,968	)		(1,148	)		9,196
	Interest income		112			11			1			124
	Interest expense		(1,427	)		(302	)		(165	)		(1,894	)
	Other non-operating expense, net		(14	)		(166	)		3,697			3,517
	Income (loss) before income taxes	$	20,983		$	(12,425	)	$	2,385		$	10,943
	Capital expenditures	$	40		$	105		$	23		$	168
	As of December 31, 2013
	Property and equipment, net	$	869		$	112		$	175		$	1,156
	Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,684		$	136,877
	(In thousands)	Americas			Europe			Asia			Consolidated
	Year Ended December 31, 2012
	Research and development revenue	$	6,189		$	-		$	15,356		$	21,545
	Product royalty revenue		50,696			-			-			50,696
	Product sales revenue		-			14			5,023			5,037
	Co-promotion revenue		3,576			-			-			3,576
	Contract and collaboration revenue		565			16			52			633
	Total revenues		61,026			30			20,431			81,487
	Cost of goods sold		98			9			2,923			3,030
	Research and development expenses		7,809			9,571			3,912			21,292
	Depreciation and amortization		484			964			40			1,488
	Other operating expenses		41,410			2,993			2,957			47,360
	Income (loss) from operations		11,225			(13,507	)		10,599			8,317
	Interest income		161			16			2			179
	Interest expense		-			(2,183	)		(163	)		(2,346	)
	Other non-operating expense, net		77			(187	)		1,937			1,827
	Income (loss) before income taxes	$	11,463		$	(15,861	)	$	12,375		$	7,977
	Capital expenditures	$	401		$	3,470		$	-		$	3,871

Note_18_Quarterly_Financial_Da1

Note 18 - Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]		2014 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun		31-Mar
	Total revenues	$	37,757	$	31,463		$	24,069	$	22,161
	Income from operations	$	17,048	$	3,643		$	3,811	$	2,729
	Net income	$	9,283	$	1,480		$	1,610	$	755
	Net income per share:
	Basic	$	0.21	$	0.03		$	0.04	$	0.02
	Diluted	$	0.21	$	0.03		$	0.04	$	0.02
		2013 Quarters Ended
	(In thousands, except per share data)	31-Dec		30-Sep			30-Jun		31-Mar
	Total revenues	$	24,490	$	21,163		$	27,023	$	16,919
	Income (loss) from operations	$	2,679	$	(1,044	)	$	10,169	$	(2,608	)
	Net income (loss)	$	2,323	$	1,523		$	6,245	$	(3,076	)
	Net income (loss) per share:
	Basic	$	0.06	$	0.04		$	0.15	$	(0.07	)
	Diluted	$	0.05	$	0.04		$	0.15	$	(0.07	)

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Summary of Valuation Allowance [Table Text Block]	(In thousands)	Balance at		Additions			Deductions				Balance at
		Beginning		Charged to							End of Year
		of Year		Costs and
				Expenses
	Allowance for doubtful accounts:
	2012	$	-	$	280	(a)	$	-			$	280
	2013	$	280	$	160	(a)	$	-			$	440
	2014	$	440	$	364	(a)	$	(779	)	(b)	$	25
	Valuation allowance for deferred tax assets:
	2012	$	4,467	$	1,073	(c)	$	(1,398	)	(c)	$	4,142
	2013	$	4,142	$	-		$	(2,391	)	(d)	$	1,751
	2014	$	1,751	$	381	(e)	$	-			$	2,132

Note_1_Business_Organization_a2

Note 1 - Business Organization and Basis of Presentation (Details)	12 Months Ended					3 Months Ended				12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2014	Dec. 31, 2014	Oct. 31, 2004	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Oct. 31, 2014	Dec. 31, 2014
	USD ($)	USD ($)	Up-front Payment Arrangement [Member]	Up-front Payment Arrangement [Member]	Up-front Payment Arrangement [Member]	RESCULA [Member]	The Abbott Agreement [Member]	The Abbott Agreement [Member]	Global License Agreement [Member]	Takeda [Member]
			Global License Agreement [Member]	Takeda [Member]	Takeda [Member]	USD ($)	USD ($)	JPY (¥)	Takeda [Member]
			Takeda [Member]	USD ($)	USD ($)				USD ($)
			USD ($)
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue to be Recognized							$2,500,000
Revenue Recognition, Milestone Method, Sales Revenue Milestone (in Yen)								5,000,000,000
Deferred Revenue	7,169,000	7,534,000	14,000,000	2,400,000	17,600,000
Contingent Commerical Milestone Payments									35,000,000
Development Expenses to be Assumed									6,000,000
Impairment of Intangible Assets, Finite-lived	$5,631,000					$5,600,000
Additioinal Reformulation Costs Funded, Percentage										100.00%

Note_1_Business_Organization_a3

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other assets	$306			$483	$488				$306	$488
Total assets	141,574				136,877				141,574	136,877
Other liabilities	1,936			679	1,233				1,936	1,233
Total liabilities	59,262			77,922	77,908				59,262	77,908
Accumulated deficit	-13,732			-26,061	-26,860				-13,732	-26,860
Total stockholders' equity	82,312			66,351	58,969				82,312	58,969	43,255	38,594
Consolidated Statements of Operations and Comprehensive Income
Other income (expense), net				-199					1,250	3,517	1,827
Total non-operating income (expense), net				-542					-98	1,747	-340
Income (loss) before income taxes				2,063					27,133	10,943	7,977
Income tax benefit (provision)				-1,308					14,005	3,928	2,916
Net income	9,283	1,480	1,610	755	2,323	1,523	6,245	-3,076	13,128	7,015	5,061
Net income per share: Basic (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.06	$0.04	$0.15	($0.07)	$0.30	$0.17	$0.12
Net income per share: Diluted (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.05	$0.04	$0.15	($0.07)	$0.29	$0.16	$0.12
Comprehensive income				644					11,792	6,450	3,373
Net cash provided by (used in) operating activities									30,878	-4,209	12,000
Net cash provided by (used in) investing activities									12,959	-12,616	-589
Effect of exchange rates on cash and cash equivalents									-904	-1,676	-1,605
Scenario, Previously Reported [Member]
Other assets				455	584					584
Total assets					136,973					136,973
Other liabilities				1,596	2,150					2,150
Total liabilities				78,839	78,825					78,825
Accumulated deficit				-27,006	-27,681					-27,681
Total stockholders' equity				65,406	58,148					58,148
Consolidated Statements of Operations and Comprehensive Income
Other income (expense), net				-323						2,921	1,602
Total non-operating income (expense), net				-666						1,151	-565
Income (loss) before income taxes				1,939						10,347	7,752
Income tax benefit (provision)				-1,264
Net income				675						6,419	4,836
Net income per share: Basic (in Dollars per share)										$0.15
Net income per share: Diluted (in Dollars per share)										$0.15
Comprehensive income				564						5,854	3,148
Net cash provided by (used in) operating activities										-5,418
Net cash provided by (used in) investing activities										-13,881
Effect of exchange rates on cash and cash equivalents										798
Restatement Adjustment [Member]
Other assets				28	-96					-96
Total assets					-96					-96
Other liabilities				-917	-917					-917
Total liabilities				-917	-917					-917
Accumulated deficit				945	821					821
Total stockholders' equity				945	821					821
Consolidated Statements of Operations and Comprehensive Income
Other income (expense), net				124						596	225
Total non-operating income (expense), net				124						596	225
Income (loss) before income taxes				124						596	225
Income tax benefit (provision)				-44
Net income				80						596	225
Net income per share: Basic (in Dollars per share)										$0.02
Net income per share: Diluted (in Dollars per share)										$0.01
Comprehensive income				80						596	225
Net cash provided by (used in) operating activities										1,209
Net cash provided by (used in) investing activities										1,265
Effect of exchange rates on cash and cash equivalents										($2,474)

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents	$2,400,000	$28,600,000
Cash, FDIC Insured Amount	37,000,000	16,400,000
PercentageOfDepositWithinFederallyInsuredLimits	33.60%	17.10%
Allowance for Doubtful Accounts Receivable	25,000	440,000
Allowance for Doubtful Accounts Receivable, Write-offs	779,000
NumberOfWholesalersInConcentrationPercentage	3
Revenue Recognition, Milestone Method, Revenue Recognized		8,000,000
Deferred Revenue	7,169,000	7,534,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate, Minimum	10.00%	10.00%	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate, Maximum	30.94%	30.94%	30.94%
Amortization period of deferred charges	10 years
Benefit Related to Partial Reversal of Internal Transfer			1,900,000
Increase (Decrease) in Deferred Charges			-23,800,000
Increase (Decrease) in Deferred Tax Liabilities			-24,100,000
Deferred Costs	2,000,000	5,200,000
Amortization of Deferred Charges	3,200,000	673,000
Liability for Uncertain Tax Positions	842,000	679,000
Unrecognized Tax Benefits, Period Increase (Decrease)	163,000
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	263,000
Computer and Office Machines [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Furniture and Fixtures [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Takeda [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	71.30%	81.30%	74.40%
Takeda [Member] | Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	88.50%	88.20%
Abbott [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	27.80%	17.60%	19.30%
Wholesale [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	89.00%	96.20%
Other Current Liabilities [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Liability for Uncertain Tax Positions, Current	263,000	42,000
Other Liabilities [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Liability for Uncertain Tax Positions, Noncurrent	$579,000	$637,000

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Deferred Revenue (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$2,051	$1,365
Deferred revenue	5,118	6,169
Total	7,169	7,534
R-Tech [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	453	477
Deferred revenue	4,141	4,925
Total	$4,594	$5,402

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted [Line Items]
Expected volatility	70.00%	65.00%	62.00%
Risk-free interest rate	1.63%	1.23%	0.76%
Expected term (in years)	5 years 102 days	5 years 6 months	5 years 6 months
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) - Assumptions Used to Estimate Fair Value of Stock Options Granted [Line Items]
Expected volatility	72.00%	75.00%	64.00%
Risk-free interest rate	2.01%	1.40%	1.60%
Expected term (in years)	6 years 3 months	6 years 3 months	6 years 3 months

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies (Details) - Employee Stock-based Compensation Expense (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation expense	$2,287	$1,744	$2,233
Employee stock-based compensation expense per basic and diluted share of common stock (in Dollars per share)	$0.05	$0.04	$0.05
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation expense	349	293	535
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation expense	1,816	1,260	1,349
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee stock-based compensation expense	$122	$191	$349

Note_3_Net_Income_Per_Share_De

Note 3 - Net Income Per Share (Details) - Net Income (Loss) per Share (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basic net income per share:
Net income (in Dollars)	$9,283	$1,480	$1,610	$755	$2,323	$1,523	$6,245	($3,076)	$13,128	$7,015	$5,061
Weighted average class A and B common shares outstanding									43,691	41,716	41,660
Assumed exercise of stock options under the treasury stock method									815	828	125
									44,506	42,544	41,785
Diluted net income per share (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.05	$0.04	$0.15	($0.07)	$0.29	$0.16	$0.12
Basic net income per share (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.06	$0.04	$0.15	($0.07)	$0.30	$0.17	$0.12

Note_3_Net_Income_Per_Share_De1

Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities	815	828	125
Employee Stock Option [Member]
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities	1,124	2,129	2,811
Non-Employee Stock Options [Member]
Note 3 - Net Income Per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities	255	410	450

Note_3_Net_Income_Per_Share_De2

Note 3 - Net Income Per Share (Details) - Antidilutive Securities (Employee Stock Options [Member])	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Employee stock options	3,012	530	596

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Investments Schedule [Abstract]
Cash and Cash Equivalents, Fair Value Disclosure	$28

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Current and Non-Current Investments (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
US Government Agencies Debt Securities [Member] | Current [Member]
Current:
Cost	$4,203
Unrealized gains	1
Fair value	4,204
Certificates of Deposit [Member] | Current [Member]
Current:
Cost	2,500	3,500
Fair value	2,500	3,500
Certificates of Deposit [Member] | Non-current [Member]
Current:
Cost	5,000	2,500
Fair value	5,000	2,500
Corporate Bond Securities [Member] | Current [Member]
Current:
Cost	4,575	752
Unrealized losses	-3
Fair value	4,572	752
Corporate Bond Securities [Member] | Non-current [Member]
Current:
Cost	509	511
Unrealized losses	-1	-1
Fair value	508	510
Commercial Paper [Member] | Current [Member]
Current:
Cost	11,109	1,000
Unrealized gains	8
Fair value	11,117	1,000
US Treasury and Government [Member] | Current [Member]
Current:
Cost		9,048
Unrealized gains		3
Fair value		9,051
US Treasury and Government [Member] | Non-current [Member]
Current:
Cost	8,047	4,212
Unrealized losses	-15	-3
Fair value	8,032	4,209
Municipal Notes [Member] | Current [Member]
Current:
Cost		1,700
Fair value		1,700
Current [Member]
Current:
Cost	22,387	16,000
Unrealized gains	9	3
Unrealized losses	-3
Fair value	22,393	16,003
Non-current [Member]
Current:
Cost	13,556	7,223
Unrealized losses	-16	-4
Fair value	$13,540	$7,219

Note_4_Current_and_NonCurrent_4

Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
US Treasury and Government [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$14,850	$1,000
US Treasury and Government [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	14,850	1,000
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	12,686
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	12,686
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	15,092	13,260
Commercial Paper [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	15,092	13,260
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	8,000	1,700
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	8,000	1,700
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,181	6,000
Corporate Bond Securities [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,181	6,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	3,111
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		5,533
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	3,111	5,533
Municipal Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		6,449
Municipal Notes [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		6,449
Variable Rate Demand Obligation [Member] | Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		5,955
Variable Rate Demand Obligation [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		5,955
Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	3,111	5,955
Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	60,809	33,942
Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$63,920	$39,897

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation	$422,000	$512,000	$542,000

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Property and Equipment Summary (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$4,510	$4,531
Less: accumulated depreciation	-3,747	-3,375
Total	763	1,156
Computer and Office Machines [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,622	2,607
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	473	480
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$1,415	$1,444

Note_6_Intangible_Assets_Detai

Note 6 - Intangible Assets (Details) (USD $)	12 Months Ended		3 Months Ended	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2012	Sep. 30, 2014	Dec. 31, 2013	Apr. 30, 2009
Note 6 - Intangible Assets (Details) [Line Items]
Payments to Acquire Intangible Assets		$3,000,000
Finite-Lived Intangible Asset, Useful Life	10 years
RESCULA [Member] | Americas [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			1,500,000
RESCULA [Member] | Europe [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			4,100,000
RESCULA [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			5,600,000
Other Noncurrent Assets [Member] | 2009 R-Tech Agreement [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-lived Intangible Assets Acquired				3,400,000
2009 R-Tech Agreement [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)			4,100,000
Payments to Acquire Intangible Assets					3,500,000
Asset Impairment Charges			1,500,000
Amortization of Intangible Assets	227,000			341,000
Finite-Lived Intangible Assets, Net				1,800,000
2011 R-Tech Agreement [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Payments to Acquire Intangible Assets			6,000,000
Finite-lived Intangible Assets Acquired	6,000,000
Amortization of Intangible Assets	409,000			613,000
Finite-Lived Intangible Assets, Net				$4,400,000

Note_7_Accrued_Expenses_Detail

Note 7 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]
Research and development costs	$3,537	$1,775
Employee compensation	3,459	2,531
Selling and marketing costs	163	584
Legal service fees	612	14
Other accrued expenses	696	778
Total	$8,467	$5,682

Note_8_Collaboration_Obligatio1

Note 8 - Collaboration Obligation (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2014	Oct. 31, 2004
Note 8 - Collaboration Obligation (Details) [Line Items]
Deferred Revenue	$7,169,000	$7,534,000
Up-front Payment Arrangement [Member] | Global License Agreement [Member] | Takeda [Member]
Note 8 - Collaboration Obligation (Details) [Line Items]
Deferred Revenue			14,000,000
Up-front Payment Arrangement [Member] | Takeda [Member]
Note 8 - Collaboration Obligation (Details) [Line Items]
Deferred Revenue	2,400,000			17,600,000
Global License Agreement [Member] | Takeda [Member]
Note 8 - Collaboration Obligation (Details) [Line Items]
Development Expenses to be Assumed			$6,000,000

Note_9_Other_Current_Liabiliti2

Note 9 - Other Current Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 9 - Other Current Liabilities (Details) [Line Items]
Defined Benefit Plan, Funded Status of Plan	($977,000)
Defined Benefit Plan, Benefit Obligation	2,769,000	1,708,000
Net Income 1 [Member] | SWITZERLAND
Note 9 - Other Current Liabilities (Details) [Line Items]
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)	11,000
Total Comprehensive Income [Member] | SWITZERLAND
Note 9 - Other Current Liabilities (Details) [Line Items]
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)	355,000
SWITZERLAND
Note 9 - Other Current Liabilities (Details) [Line Items]
Defined Benefit Plan, Minimum Investment Return	1.75%	1.50%
Defined Benefit Plan, Funded Status of Plan	-977,000
Defined Benefit Plan, Assets for Plan Benefits	1,800,000
Defined Benefit Plan, Benefit Obligation	2,800,000
Pension Expense	221,000
Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)	$366,000

Note_9_Other_Current_Liabiliti3

Note 9 - Other Current Liabilities (Details) - Other Current Liabilities Summary (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Current Liabilities Summary [Abstract]
Indirect taxes payable	$3,075
Other liabilities	543	358
Total	$3,618	$358

Note_10_Other_Liabilities_Deta

Note 10 - Other Liabilities (Details) - Other Liabilities Summary (USD $)	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Summary [Abstract]
Deferred leasehold incentive	$137		$255
Deferred rent expense	243		341
Defined benefit obligation	977
Other liabilities	579		637
Total	$1,936	$679	$1,233

Note_10_Other_Liabilities_Deta1

Note 10 - Other Liabilities (Details) - Reconciliation of Projected Benefit Obligation and Fair Value of Plan Assets (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Reconciliation of Projected Benefit Obligation and Fair Value of Plan Assets [Abstract]
Projected benefit obligation at beginning of year	$1,708
Service cost	191
Interest cost	43
Plan participantsb contributions	165
Actuarial loss (gain)	653
Benefits paid	83
Expenses paid	-8
Premiums paid	-66
Projected benefit obligation at end of year	2,769
Fair value of plan assets at end of year	1,792
Funded status at end of year	-977
Fair value of plan assets at beginning of year	1,342
Actual return on plan assets	42
Employer contribution	$234

Note_10_Other_Liabilities_Deta2

Note 10 - Other Liabilities (Details) - Reconciliation of Amounts Recognized in Consolidated Statements of Operations and Comprehensive Income (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Reconciliation of Amounts Recognized in Consolidated Statements of Operations and Comprehensive Income [Abstract]
Net loss	($978)
Total amount recognized in accumulated other comprehensive income	-978
Accumulated contributions in excess of net periodic benefit cost	1
Funded status at end of year	($977)

Note_10_Other_Liabilities_Deta3

Note 10 - Other Liabilities (Details) - Net Periodic Benefit Cost Recognized (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Net Periodic Benefit Cost Recognized [Abstract]
Service cost	$191
Interest cost	43
Expected return on assets	-30
Amortization of unrecognized net loss	17
Net periodic pension cost	$221

Note_10_Other_Liabilities_Deta4

Note 10 - Other Liabilities (Details) - Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income [Abstract]
Net loss arising during year	$641
Amortization or settlement of net loss	-17
Total recognized in other comprehensive income	624
Total loss recognized in net periodic cost and other comprehensive income	$845

Note_10_Other_Liabilities_Deta5

Note 10 - Other Liabilities (Details) - Estimated Amounts to be Amortized From Accumulated Other Comprehensive Income Over the Next Year (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Estimated Amounts to be Amortized From Accumulated Other Comprehensive Income Over the Next Year [Abstract]
Net loss	$73

Note_10_Other_Liabilities_Deta6

Note 10 - Other Liabilities (Details) - Projected Benefit Obligations in Excess of Plan Assets (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Projected Benefit Obligations in Excess of Plan Assets [Abstract]
Projected benefit obligation	$2,769
Accumulated benefit obligation	2,469
Fair value of plan assets	$1,792

Note_10_Other_Liabilities_Deta7

Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets	Dec. 31, 2014
Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets [Line Items]
Weighted average allocation of plan assets	100.00%
Debt Securities [Member]
Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets [Line Items]
Weighted average allocation of plan assets	79.00%
Real Estate [Member]
Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets [Line Items]
Weighted average allocation of plan assets	12.00%
Other Investments 1 [Member]
Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets [Line Items]
Weighted average allocation of plan assets	6.00%
Cash [Member]
Note 10 - Other Liabilities (Details) - Weighted Average Allocation of Plan Assets [Line Items]
Weighted average allocation of plan assets	3.00%

Note_10_Other_Liabilities_Deta8

Note 10 - Other Liabilities (Details) - Assumptions Used to Determine Net Periodic Pension Cost and Future Benefit Obligations	12 Months Ended
	Dec. 31, 2014
Assumptions Used to Determine Net Periodic Pension Cost and Future Benefit Obligations [Abstract]
Discount or settlement rates	2.50%
Expected long-term rates of return on assets	2.10%
Rates of increase in compensation levels	1.50%
Discount rate	1.00%
Rates of increase in compensation levels	1.50%

Note_10_Other_Liabilities_Deta9

Note 10 - Other Liabilities (Details) - Expected Future Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Employee Contributions
2015	$151
Benefit Payments
2015	145
2016	10
2017	14
2018	18
2019	23
2020-2024	$494

Note_11_Commitments_and_Contin2

Note 11 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 11 - Commitments and Contingencies (Details) [Line Items]
Operating Leases, Rent Expense	$1.40	$1.50	$1.60
Future Estimated Research and Development Costs		8.5
Guarantee of Indebtedness of Others [Member]
Note 11 - Commitments and Contingencies (Details) [Line Items]
Loss Contingency, Range of Possible Loss, Maximum	2.2
Loss Contingency, Estimate of Possible Loss	$2

Note_11_Commitments_and_Contin3

Note 11 - Commitments and Contingencies (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum, Non-Cancelable Lease Payments [Abstract]
2015	$1,198
2016	1,189
2017	244
2018	104
Total minimum lease payments	$2,735

Note_12_Related_Party_Transact2

Note 12 - Related Party Transactions (Details)	144 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2011	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	CHF	Numab [Member]	Numab [Member]	Numab [Member]	Numab [Member]	Numab [Member]
			Guarantee of Indebtedness of Others [Member]	Guarantee of Indebtedness of Others [Member]	Zurcher Kantonalbank [Member]	USD ($)	CHF
			USD ($)	USD ($)	CHF
Note 12 - Related Party Transactions (Details) [Line Items]
Related Party Transaction, Amounts of Transaction	$9,000,000
Loans Pledged as Collateral		2,200,000			5,000,000	2,200,000
Long-term Debt, Gross						2,000,000	2,000,000
Guarantor Obligations, Current Carrying Value			$1,000,000	$663,000

Note_12_Related_Party_Transact3

Note 12 - Related Party Transactions (Details) - Expenses under Agreements with R-Tech (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Expenses related to R-Tech	$16,343	$15,923	$5,204
Clinical Supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	396	827	1,450
Other research and development services [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	171	194	466
Commercial supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	$15,776	$14,902	$3,288

Note_12_Related_Party_Transact4

Note 12 - Related Party Transactions (Details) - Deferred Revenues Under the Companybs Agreements With R-Tech (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	$2,051	$1,365
Deferred revenue, non-current	5,118	6,169
	7,169	7,534
R-Tech [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	453	477
Deferred revenue, non-current	4,141	4,925
	$4,594	$5,402

Note_13_Notes_Payable_Details

Note 13 - Notes Payable (Details)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2010

Dec. 01, 2014

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Nov. 30, 2010

Nov. 30, 2010

Dec. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

USD ($)

Ueno Trust [Member]

Kuno and Ueno Trust [Member]

Kuno and Ueno Trust [Member]

Kuno and Ueno Trust [Member]

Subordinated Unsecured Promissory Notes [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

USD ($)

Tokyo-Mitsubishi Bank [Member]

Tokyo-Mitsubishi Bank [Member]

Tokyo-Mitsubishi Bank [Member]

Tokyo-Mitsubishi Bank [Member]

Mizuho Bank Limited [Member]

Mizuho Bank Limited [Member]

Mizuho Bank Limited [Member]

Mizuho Bank Limited [Member]

USD ($)

London Interbank Offered Rate (LIBOR) [Member]

USD ($)

USD ($)

USD ($)

JPY (¥)

USD ($)

USD ($)

JPY (¥)

Note 13 - Notes Payable (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$11,600,000

¥ 1,000,000,000

$10,600,000

¥ 1,000,000,000

Long-term Line of Credit

9,500,000

9,500,000

PercentageCollateralToLoans

90.00%

100.00%

Interest-bearing Deposits in Banks and Other Financial Institutions

14,900,000

11,000,000

Debt Instrument, Face Amount

25,900,000

51,900,000

Debt Instrument, Basis Spread on Variable Rate

4.00%

Debt Instrument, Interest Rate, Stated Percentage

4.30%

Paid-in-Kind Interest

$2,024,000

$2,200,000

Note_13_Notes_Payable_Details_

Note 13 - Notes Payable (Details) - Notes Payable (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 13 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	$26,317
Note Payable Carrying Value	25,818	52,720
Notes payable, current	8,240	26,892
Notes payable, non-current	17,578	25,828
Mizuho Bank Limited [Member]
Note 13 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Carrying Value		19,008
SAG [Member]
Note 13 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	26,317
Note Payable Carrying Value	$25,818	$33,712

Note_14_Collaboration_and_Lice2

Note 14 - Collaboration and License Agreements (Details) (USD $)	12 Months Ended			1 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 29, 2008	Jun. 30, 2013	Dec. 31, 2006	Dec. 31, 2014	Jun. 30, 2007	Oct. 31, 2004	Oct. 31, 2014
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized		$8,000,000
Deferred Revenue	7,169,000	7,534,000					7,169,000
Royalty Revenue	62,775,000	52,100,000	50,696,000
Deferred Revenue, Noncurrent	5,118,000	6,169,000					5,118,000
Copromotion Revenue	3,360,000	61,000	3,576,000
Sales Revenue, Goods, Net	33,252,000	16,425,000	5,037,000
Collaboration Revenue [Member] | Up-front Payment Arrangement [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Deferred Revenue, Revenue Recognized	147,000	147,000	147,000
Research and Development Expense [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized				50,000,000
Up Front Fee And Milestone Payment Arrangement [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	160,000,000
Up Front Fee And Milestone Payment Arrangement [Member] | Abbott [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	37,500,000
Milestone Payment Arrangement [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized					10,000,000
Deferred Revenue									50,000,000
Milestone Payment Arrangement [Member] | Abbott [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized			15,000,000
Up-front Payment Arrangement [Member] | Global License Agreement [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Deferred Revenue										14,000,000
Up-front Payment Arrangement [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	20,000,000
Deferred Revenue	2,400,000						2,400,000		17,600,000
Reimbursement of Research and Development Expenses [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Deferred Revenue, Noncurrent									30,000,000
For Each Additional Indication [Member] | Maximum [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Funded Development Costs, Counterparty Obligation, Amount						50,000,000
For Each New Formulation [Member] | Maximum [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Funded Development Costs, Counterparty Obligation, Amount						20,000,000
Global License Agreement [Member] | Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized							14,000,000
Contingent Commerical Milestone Payments										35,000,000
Development Expenses to be Assumed										6,000,000
Licenses Revenue							8,000,000
Contractual Obligation	6,000,000						6,000,000
The Abbott Agreement [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Sales Revenue, Goods, Net	32,100,000	15,800,000
Abbott [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	2,500,000
Takeda [Member]
Note 14 - Collaboration and License Agreements (Details) [Line Items]
Royalty Revenue	62,800,000	52,100,000	50,700,000
Initial Funded Development Costs, Amount									30,000,000
Entity Funded Development Costs									20,000,000
Collaborative Funded Development Costs, Minimum									50,000,000
Contracts Revenue								30,000,000
Number of Studies in Joint Commercialization						3
Funding Labeling Studies, Percentage						70.00%
Company Funded Labeling Studies, Percentage						30.00%
Copromotion Revenue	$3,400,000	$61,000	$3,600,000

Note_14_Collaboration_and_Lice3

Note 14 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Takeda Agreement (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2012	Dec. 31, 2013	Oct. 31, 2004
Deferred Revenue Arrangement [Line Items]
Amount deferred	$7,169,000			$7,534,000
Up-front Payment Arrangement [Member] | Research and Development Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	17,624,000
Revenue recognized			17,624,000
Accounts receivable		[1]
Up-front Payment Arrangement [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Amount deferred	2,400,000				17,600,000
Development Milestone [Member] | Research and Development Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	140,000,000
Revenue recognized			130,000,000	10,000,000
Accounts receivable		[1]
Reimbursement of Research and Development Expenses [Member] | Research and Development Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	123,087,000
Revenue recognized	7,221,000		106,451,000	10,354,000
Accounts receivable	939,000	[1]
Collaborative Arrangement [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	2,375,000
Revenue recognized	147,000		1,199,000	147,000
Accounts receivable		[1]
Amount deferred	882,000
Research and Development Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	280,711,000
Revenue recognized	7,221,000		254,075,000	20,354,000
Accounts receivable	939,000	[1]
Product Royalty Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	335,626,000
Revenue recognized	62,775,000		239,327,000	52,100,000
Accounts receivable	18,576,000	[1]
Co-Promotion Revenue [Member] | Takeda [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	31,475,000
Revenue recognized	3,360,000		29,392,000	61,000
Accounts receivable	$1,338,000	[1]
[1]	Includes billed and unbilled accounts receivable.

Note_14_Collaboration_and_Lice4

Note 14 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Japan Abbott Agreement (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]
Amount deferred	$7,169,000	$7,534,000
Up Front Payment Remainder [Member] | Research and Development Revenue [Member] | Abbott [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	9,154,000
Revenue recognized			9,302,000
Foreign currency effects	-148,000
Development Milestone [Member] | Research and Development Revenue [Member] | Abbott [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	27,500,000
Revenue recognized			27,755,000
Foreign currency effects	-255,000
Collaborative Arrangement [Member] | Abbott [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	846,000
Revenue recognized	39,000	52,000	189,000
Foreign currency effects	113,000
Amount deferred	453,000
Research and Development Revenue [Member] | Abbott [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	36,654,000
Revenue recognized			37,057,000
Foreign currency effects	-403,000
Product Sales Revenue [Member] | Abbott [Member]
Deferred Revenue Arrangement [Line Items]
Cash received	50,902,000
Revenue recognized	32,088,000	15,807,000	5,023,000
Accounts receivable	1,980,000
Foreign currency effects	($36,000)

Note_15_Stockholders_Equity_De

Note 15 - Stockholders' Equity (Details) (USD $)	12 Months Ended			24 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Aug. 05, 2005	Jan. 11, 2013	Jun. 05, 2006	Nov. 02, 2012	Sep. 11, 2009	Dec. 11, 2008
Note 15 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Common Stock (in Dollars)	$5,326,000	$5,281,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$7.68	$7.36	$6.30
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	7,600,000			7,600,000
Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)	36,000	25,000	20,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation (in Dollars)	113,000	213,000		325,000
Common Class A [Member] | Cantor Sales Agreement [Member] | Cantor Fitzgerald & Co [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Sales Agreement, Common Stock, Maximum Aggregate Sales Price (in Dollars)						20,000,000
Common Class A [Member] | Cantor Sales Agreement [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	538,521	749,383
Proceeds from Issuance of Common Stock (in Dollars)	5,500,000	5,300,000
Common Class A [Member] | Stock Plan 2001 [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		8,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					510,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)					$5.85
Common Class A [Member] | Stock Incentive Plan 2006 [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							8,500,000
Annual Increase in Number of Shares Issuance	500,000
Common Class A [Member] | 2006 Employee Stock Purchase Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	5,853	3,625	3,550
Stock Issued During Period, Value, Employee Stock Purchase Plan (in Dollars)	35,000	24,000	20,000
Common Class A [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Common Stock, Voting Rights, Votes per Share	1			1
Stock Repurchase Program, Authorized Amount (in Dollars)								5,000,000	2,000,000	10,000,000
Stock Repurchased During Period, Shares	0	67,762
Stock Repurchased During Period, Value (in Dollars)		$336,000
Common Stock, Shares Authorized	270,000,000	270,000,000		270,000,000
Non-Employee Stock Options [Member] | Stock Plan 2001 [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	255,000	410,000		255,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		1 year 120 days
Employee Stock Option [Member] | Stock Plan 2001 [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	113,900	255,000		113,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	339 days	2 years 124 days
Employee Stock Option [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 146 days
Performance Shares [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Investment Options, Exercise Price (in Dollars per share)	$16
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	4 years
Accelerated-vesting Stock Options [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	450,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Time-Based Stock Options [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,053,245
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Cantor Sales Agreement [Member] | Cantor Fitzgerald & Co [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Sales Agreement, Commission Rate as a Percentage of Gross Sales						3.00%
One Instance of Option Exercises [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	69,499
Stock Issued During Period, Shares, Share-based Compensation, Gross	32,870
Stock Incentive Plan 2006 [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,703,995
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$7.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	937,765			937,765
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,195,271			3,195,271
Share-based Compensation Arrangement by Share-based Payment Award, Increase in Common Stock Available for Issuance as Percentage of Aggregate Number of Shares Outstanding	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	618,377
2006 Employee Stock Purchase Plan [Member]
Note 15 - Stockholders' Equity (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance							4,250,000
Common Stock, Shares Authorized	500,000			500,000
Share-Based Compensation, Percentage of Compensation to Purchase Common Stock	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%

Note_15_Stockholders_Equity_De1

Note 15 - Stockholders' Equity (Details) - Employee Stock Option Activity (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Non Employee Stock Plan 2001 [Member]
Note 15 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	255,000	410,000
Options Outstanding, Weighted Average Exercise Price Per Share	$5.85	$5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	3 months
Options Outstanding, Aggregate Intrinsic Value	$2,149,650
Options exercisable	255,000
Options exercisable, Weighted Average Exercise Price Per Share	$5.85
Options exercisable, Weighted Average Remaining Contractual Term (Years)	3 months
Options exercisable, Aggregate Intrinsic Value	2,149,650
Options exercised	-155,000
Options exercised, Weighted Average Exercise Price Per Share	$5.85
2001 Incentive Plan [Member]
Note 15 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	113,900	146,200
Options Outstanding, Weighted Average Exercise Price Per Share	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	339 days
Options Outstanding, Aggregate Intrinsic Value	487,492
Options exercisable	113,900
Options exercisable, Weighted Average Exercise Price Per Share	$10
Options exercisable, Weighted Average Remaining Contractual Term (Years)	339 days
Options exercisable, Aggregate Intrinsic Value	487
Options exercised	-6,800
Options exercised, Weighted Average Exercise Price Per Share	$10
Options expired	-25,500
Options expired, Weighted Average Exercise Price Per Share	$10
Stock Incentive Plan 2006 [Member]
Note 15 - Stockholders' Equity (Details) - Employee Stock Option Activity [Line Items]
Options Outstanding	4,021,491	2,513,063
Options Outstanding, Weighted Average Exercise Price Per Share	$6.93	$5.03
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 208 days
Options Outstanding, Aggregate Intrinsic Value	29,560,979
Options granted	2,703,995
Options granted	$7.68
Options exercisable	937,765
Options exercisable, Weighted Average Exercise Price Per Share	$6.02
Options exercisable, Weighted Average Remaining Contractual Term (Years)	6 years 29 days
Options exercisable, Aggregate Intrinsic Value	$7,746,764
Options exercised	-618,377
Options exercised, Weighted Average Exercise Price Per Share	$4.54
Options forfeited	-383,915
Options forfeited	$4.72
Options expired	-193,275
Options expired, Weighted Average Exercise Price Per Share	$4.81

Note_16_Income_Taxes_Details

Note 16 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 16 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$1,400,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	4,500,000
Deferred Tax Assets, Valuation Allowance	2,132,000	1,751,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	381,000	-2,400,000	-325,000
Benefit Related to Partial Reversal of Internal Transfer			1,900,000
Increase (Decrease) in Deferred Charges			-23,800,000
Increase (Decrease) in Deferred Tax Liabilities			-24,100,000
Deferred Costs	2,000,000	5,200,000
Amortization of Deferred Charges	3,200,000	673,000
Liability for Uncertain Tax Positions	842,000	679,000
Unrecognized Tax Benefits, Interest on Income Taxes Expense	1,000	22,000	42,000
Open Tax Year	2014	2013	2012	2011
Foreign Tax Authority [Member]
Note 16 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	5,900,000	11,900,000
Domestic Tax Authority [Member] | Minimum [Member]
Note 16 - Income Taxes (Details) [Line Items]
Open Tax Year	2009
Domestic Tax Authority [Member] | Maximum [Member]
Note 16 - Income Taxes (Details) [Line Items]
Open Tax Year	2011
Domestic Tax Authority [Member]
Note 16 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	0	0
Other Current Liabilities [Member]
Note 16 - Income Taxes (Details) [Line Items]
Liability for Uncertain Tax Positions, Current	263,000	42,000
Other Liabilities [Member]
Note 16 - Income Taxes (Details) [Line Items]
Liability for Uncertain Tax Positions, Noncurrent	$579,000	$637,000

Note_16_Income_Taxes_Details_I

Note 16 - Income Taxes (Details) - Income (Loss) Before Income Taxes (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income (Loss) Before Income Taxes [Abstract]
U.S.		$18,005	$9,175	$8,580
Foreign		9,128	1,768	-603
	$2,063	$27,133	$10,943	$7,977

Note_16_Income_Taxes_Details_P

Note 16 - Income Taxes (Details) - Provision (Benefit) for Income Taxes (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current tax provision (benefit):
U.S. Federal		$11,319	$5,198	$1,431
U.S. State		1,351	1,008	658
Foreign		793	-582	51
Total current tax provision (benefit)		13,463	5,624	2,140
Deferred provision (benefit):
U.S. Federal		-172	-1,783	1,248
U.S. State		-16	-279	-193
Foreign		730	366	-279
Total deferred provision (benefit)		542	-1,696	776
Total income tax provision (benefit)	($1,308)	$14,005	$3,928	$2,916

Note_16_Income_Taxes_Details_D

Note 16 - Income Taxes (Details) - Deferred Tax Assets (Liabilities), Net (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Foreign net operating loss carry-forwards	$1,409	$2,538
State net operating loss carry-forwards	3	38
Deferred revenue	1,803	2,143
Accrued expenses	734	1,637
Tax benefits on stock options	2,063	2,378
Inventory	615	1,243
Property and equipment	15
Other	207	220
Gross deferred tax assets	6,849	10,197
Deferred tax liabilities:
Property and equipment	-122	-202
Intangibles	-4,368	-7,070
Gross deferred tax liabilities	-4,490	-7,272
Less: valuation allowance	-2,132	-1,751
Net deferred tax assets (liabilities)	$227	$1,174

Note_16_Income_Taxes_Details_I1

Note 16 - Income Taxes (Details) - Income Taxes on The Federal Statutory Rate	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes on The Federal Statutory Rate [Abstract]
Federal tax provision (benefit)	35.00%	35.00%	34.00%
State taxes, net of federal tax benefit	2.10%	4.90%	7.30%
General business credits	0.00%	0.00%	-0.50%
Changes in valuation allowance	1.40%	-21.60%	-3.90%
Nondeductible expenses	1.70%	1.30%	1.60%
Stock based compensation	-0.10%	-2.80%	12.30%
Impact of intangible transfer	5.80%	7.30%	-18.00%
Impact of uncertain tax positions	-0.20%	-0.10%	-4.10%
Adjustment to deferred tax asset	0.50%	11.10%	-10.10%
Impact of foreign operations	-3.70%	0.30%	5.70%
Subpart F income	9.10%	0.00%	0.00%
Change in tax rates	0.00%	0.60%	12.00%
Changes in other tax matters	0.00%	-0.10%	0.30%
	51.60%	35.90%	36.60%

Note_16_Income_Taxes_Details_U

Note 16 - Income Taxes (Details) - Unrecognized Tax Benefits Excluding Interest and Penalties (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Unrecognized Tax Benefits Excluding Interest and Penalties [Abstract]
Balance at January 1	$550	$979	$1,226
Increases for tax positions taken during prior periods	-91	4	207
Decreases in unrecognized tax benefits related to settlements with taxing authorities		-467	-536
Increases for tax positions taken during current period	253	34	82
Balance at December 31	$712	$550	$979

Note_17_Segment_Reporting_Deta

Note 17 - Segment Reporting (Details)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Number of Reportable Segments	3

Note_17_Segment_Reporting_Deta1

Note 17 - Segment Reporting (Details) - Financial Information by Reportable Geographic Segment (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Research and development revenue									$7,246,000	$20,354,000	$21,545,000
Product royalty revenue									62,775,000	52,100,000	50,696,000
Product sales revenue									33,252,000	16,425,000	5,037,000
Co-promotion revenue									3,360,000	61,000	3,576,000
Contract and collaboration revenue									8,817,000	654,000	633,000
Total revenues	37,757,000	31,463,000	24,069,000	22,161,000	24,490,000	21,163,000	27,023,000	16,919,000	115,450,000	89,594,000	81,487,000
Cost of goods sold									16,269,000	12,402,000	3,030,000
Intangible assets impairment									5,631,000
Research and development expenses									20,566,000	21,524,000	21,292,000
Depreciation and amortization									1,090,000	1,488,000	1,488,000
Other operating expenses									45,422,000	44,984,000	47,360,000
Income (loss) from operations	17,048,000	3,643,000	3,811,000	2,729,000	2,679,000	-1,044,000	10,169,000	-2,608,000	27,231,000	9,196,000	8,317,000
Interest income									172,000	124,000	179,000
Interest expense									-1,520,000	-1,894,000	-2,346,000
Other non-operating expense, net				-199,000					1,250,000	3,517,000	1,827,000
Income (loss) before income taxes				2,063,000					27,133,000	10,943,000	7,977,000
Capital expenditures									66,000	168,000	3,871,000
As of December 31, 2014
Property and equipment, net	763,000				1,156,000				763,000	1,156,000
Identifiable assets, net of intercompany loans and investments	141,574,000				136,877,000				141,574,000	136,877,000
Americas [Member]
Segment Reporting Information [Line Items]
Research and development revenue									7,246,000	20,354,000	6,189,000
Product royalty revenue									62,775,000	52,100,000	50,696,000
Product sales revenue									741,000	556,000
Co-promotion revenue									3,360,000	61,000	3,576,000
Contract and collaboration revenue									566,000	566,000	565,000
Total revenues									74,688,000	73,637,000	61,026,000
Cost of goods sold									444,000	3,588,000	98,000
Intangible assets impairment									1,502,000
Research and development expenses									11,566,000	11,090,000	7,809,000
Depreciation and amortization									601,000	736,000	484,000
Other operating expenses									32,340,000	35,911,000	41,410,000
Income (loss) from operations									28,235,000	22,312,000	11,225,000
Interest income									132,000	112,000	161,000
Interest expense									-1,364,000	-1,427,000
Other non-operating expense, net									44,000	-14,000	77,000
Income (loss) before income taxes									27,047,000	20,983,000	11,463,000
Capital expenditures									61,000	40,000	401,000
As of December 31, 2014
Property and equipment, net	566,000				869,000				566,000	869,000
Identifiable assets, net of intercompany loans and investments	111,846,000				95,350,000				111,846,000	95,350,000
Europe [Member]
Segment Reporting Information [Line Items]
Product sales revenue									422,000	62,000	14,000
Contract and collaboration revenue									8,212,000	46,000	16,000
Total revenues									8,634,000	108,000	30,000
Cost of goods sold									407,000	15,000	9,000
Intangible assets impairment									4,129,000
Research and development expenses									5,023,000	5,445,000	9,571,000
Depreciation and amortization									460,000	716,000	964,000
Other operating expenses									11,259,000	5,900,000	2,993,000
Income (loss) from operations									-12,644,000	-11,968,000	-13,507,000
Interest income									6,000	11,000	16,000
Interest expense									-9,000	-302,000	-2,183,000
Other non-operating expense, net									653,000	-166,000	-187,000
Income (loss) before income taxes									-11,994,000	-12,425,000	-15,861,000
Capital expenditures									2,000	105,000	3,470,000
As of December 31, 2014
Property and equipment, net	83,000				112,000				83,000	112,000
Identifiable assets, net of intercompany loans and investments	24,984,000				23,843,000				24,984,000	23,843,000
Asia [Member]
Segment Reporting Information [Line Items]
Research and development revenue											15,356,000
Product sales revenue									32,089,000	15,807,000	5,023,000
Contract and collaboration revenue									39,000	42,000	52,000
Total revenues									32,128,000	15,849,000	20,431,000
Cost of goods sold									15,181,000	8,799,000	2,923,000
Research and development expenses									3,455,000	4,989,000	3,912,000
Depreciation and amortization									29,000	36,000	40,000
Other operating expenses									1,823,000	3,173,000	2,957,000
Income (loss) from operations									11,640,000	-1,148,000	10,599,000
Interest income									34,000	1,000	2,000
Interest expense									-147,000	-165,000	-163,000
Other non-operating expense, net									553,000	3,697,000	1,937,000
Income (loss) before income taxes									12,080,000	2,385,000	12,375,000
Capital expenditures									3,000	23,000
As of December 31, 2014
Property and equipment, net	114,000				175,000				114,000	175,000
Identifiable assets, net of intercompany loans and investments	$4,744,000				$17,684,000				$4,744,000	$17,684,000

Note_18_Quarterly_Financial_Da2

Note 18 - Quarterly Financial Data (unaudited) (Details) - Quarterly Financial Data Summary (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Data Summary [Abstract]
Total revenues	$37,757	$31,463	$24,069	$22,161	$24,490	$21,163	$27,023	$16,919	$115,450	$89,594	$81,487
Income from operations	17,048	3,643	3,811	2,729	2,679	-1,044	10,169	-2,608	27,231	9,196	8,317
Net income	$9,283	$1,480	$1,610	$755	$2,323	$1,523	$6,245	($3,076)	$13,128	$7,015	$5,061
Net income per share:
Basic (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.06	$0.04	$0.15	($0.07)	$0.30	$0.17	$0.12
Diluted (in Dollars per share)	$0.21	$0.03	$0.04	$0.02	$0.05	$0.04	$0.15	($0.07)	$0.29	$0.16	$0.12

Schedule_II_Valuation_and_Qual2

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation and Qualifying Accounts [Abstract]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$381,000	($2,400,000)	($325,000)

Schedule_II_Valuation_and_Qual3

Schedule II - Valuation and Qualifying Accounts (Details) - Schedule II b Valuation and Qualifying Accounts (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Valuation Allowance [Line Items]
Balance at Beginning of Year	$440		$280
Charged to Costs and Expenses	364	[1]	160	[1]	280	[1]
Deductions	-779	[2]
Balance at End of Year	25		440		280
Valuation Allowance of Deferred Tax Assets [Member]
Valuation Allowance [Line Items]
Balance at Beginning of Year	1,751		4,142		4,467
Charged to Costs and Expenses	381	[3]			1,073	[4]
Deductions			-2,391	[5]	-1,398	[4]
Balance at End of Year	$2,132		$1,751		$4,142
[1]	In 2012, 2013 and 2014, the increase in allowance for doubtful accounts is associated with certain disputed Takeda invoices.
[2]	The 2014 deduction from allowance for doubtful accounts resulted from a charge-off of certain disputed Takeda invoices.
[3]	In 2014, the net increase of $381,000 in valuation allowance for deferred tax assets was primarily due to the additional NOL's in foreign jurisdictions where management believes it is more likely than not a portion of the NOL balance will expire prior to utilization.
[4]	In 2012, the net decrease in valuation allowance for deferred tax assets of $325,000 was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized.
[5]	In 2013, the net decrease in valuation allowance for deferred tax assets of $2.4 million was due primarily to the release of the valuation allowance in certain jurisdictions that management believes the deferred tax assets are more likely than not to be utilized, as well as the reversal of all deferred tax assets of Ambrent for anticipated liquidation.